Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription Articles published in Mult Scler Retrieve available abstracts of 720 articles: HTML format

Single Articles

April 2024
1. SCHNEIDER M, Kramer J, Banks A, Moses H, et al
   New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
   Mult Scler. 2024 Apr 11:13524585241242027. doi: 10.1177/13524585241242027.
   PubMed     Abstract available
   
   
   
2. MOCCIA M, Terracciano D, Brescia Morra V, Castaldo G, et al
   Neurofilament in clinical practice: Is the multiple sclerosis community ready?
   Mult Scler. 2024 Apr 11:13524585241246536. doi: 10.1177/13524585241246536.
   PubMed    
   
   
   
3. KWON S, Han KD, Jung JH, Cho EB, et al
   Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
   Mult Scler. 2024 Apr 1:13524585241237093. doi: 10.1177/13524585241237093.
   PubMed     Abstract available
   
   
   
4. ALOISI F, Salvetti M
   EBV infection drives MS pathology: Yes.
   Mult Scler. 2024;30.
   PubMed    
   
   
   
5. CORTESE M, Ascherio A
   EBV infection drives MS pathology: Commentary.
   Mult Scler. 2024;30.
   PubMed    
   
   
   
6. 'T HART BA, van Luijn MM
   EBV infection drives MS pathology: No.
   Mult Scler. 2024;30.
   PubMed    
   
   
   
7. TUR C, Battiston M, Yiannakas MC, Collorone S, et al
   What contributes to disability in progressive MS? A brain and cervical cord-matched quantitative MRI study.
   Mult Scler. 2024;30.
   PubMed     Abstract available
   
   
   
8. REEVES JA, Mohebbi M, Wicks T, Salman F, et al
   Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years.
   Mult Scler. 2024;30.
   PubMed     Abstract available
   
   
   
9. KLISTORNER S, Barnett MH, Wang C, Parratt J, et al
   Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients.
   Mult Scler. 2024;30.
   PubMed     Abstract available
   
   
   
10. SBRAGIA E, Boffa G, Varaldo R, Raiola AM, et al
    An aggressive form of MOGAD treated with aHSCT: A case report.
    Mult Scler. 2024;30.
    PubMed     Abstract available
    
    
    March 2024
11. PAPPOLLA A, Auger C, Sao-Aviles A, Tur C, et al
    Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
    Mult Scler. 2024 Mar 29:13524585241240653. doi: 10.1177/13524585241240653.
    PubMed     Abstract available
    
    
    
12. SIMPSON AC, Hu C, Mowry EM, Naismith RT, et al
    Structural MRI measures are associated with fatigue severity and persistence in a large, real-world cohort of people with multiple sclerosis.
    Mult Scler. 2024 Mar 25:13524585241239473. doi: 10.1177/13524585241239473.
    PubMed     Abstract available
    
    
    
13. SORENSEN PS, Bramow S, Magyari M, Werdelin L, et al
    Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research.
    Mult Scler. 2024 Mar 24:13524585241239506. doi: 10.1177/13524585241239506.
    PubMed     Abstract available
    
    
    
14. MAILLART E, Redolfi S, Louapre C, Houot M, et al
    Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort.
    Mult Scler. 2024 Mar 22:13524585241238840. doi: 10.1177/13524585241238840.
    PubMed     Abstract available
    
    
    
15. CAMPAGNA MP, Havrdova EK, Horakova D, Izquierdo G, et al
    No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.
    Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406.
    PubMed     Abstract available
    
    
    
16. HJALGRIM H, Rostgaard K
    Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
    Mult Scler. 2024 Mar 21:13524585241237708. doi: 10.1177/13524585241237708.
    PubMed    
    
    
    
17. GOLDACRE R
    Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003-2023.
    Mult Scler. 2024 Mar 21:13524585241237707. doi: 10.1177/13524585241237707.
    PubMed     Abstract available
    
    
    
18. JOHNSSON M, Stenberg YT, Farman HH, Blennow K, et al
    Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
    Mult Scler. 2024 Mar 13:13524585241237388. doi: 10.1177/13524585241237388.
    PubMed     Abstract available
    
    
    
19. NAKAMURA K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al
    Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
    Mult Scler. 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055.
    PubMed     Abstract available
    
    
    
20. EHLING R, Seebacher B, Brenneis C
    Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Mar 11:13524585241234789. doi: 10.1177/13524585241234789.
    PubMed    
    
    
    
21. HILLERT J, Bove R, Haddad LB, Hellwig K, et al
    Expert opinion on the use of contraception in people with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
    PubMed     Abstract available
    
    
    
22. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
    Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
    PubMed     Abstract available
    
    
    
23. KUBICKI K, Stefoski D
    Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
    Mult Scler. 2024 Mar 8:13524585241235539. doi: 10.1177/13524585241235539.
    PubMed     Abstract available
    
    
    
24. MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
    Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
    PubMed     Abstract available
    
    
    
25. GIULIANI G, Zilli C, Caramia F, Di Piero V, et al
    SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.
    Mult Scler. 2024 Mar 1:13524585241235535. doi: 10.1177/13524585241235535.
    PubMed     Abstract available
    
    
    
26. ROCCHI C, Forcadela M, Kelly P, Linaker S, et al
    The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis.
    Mult Scler. 2024;30:345-356.
    PubMed     Abstract available
    
    
    February 2024
27. AFZAL RM, Romme Christensen J, Gynthersen RMM, Lebech AM, et al
    Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report.
    Mult Scler. 2024 Feb 29:13524585241235542. doi: 10.1177/13524585241235542.
    PubMed     Abstract available
    
    
    
28. KARI S, Bucciarelli F, Angles T, Oster AC, et al
    Increased levels of circulating soluble CD226 in multiple sclerosis.
    Mult Scler. 2024 Feb 29:13524585241234489. doi: 10.1177/13524585241234489.
    PubMed     Abstract available
    
    
    
29. HEESEN C, Luhmann D
    Reply: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Feb 29:13524585241234777. doi: 10.1177/13524585241234777.
    PubMed    
    
    
    
30. LIM TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, et al
    Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
    Mult Scler. 2024 Feb 28:13524585241228426. doi: 10.1177/13524585241228426.
    PubMed     Abstract available
    
    
    
31. NAKKEN O, Aarseth JH, Wergeland S, Stigum H, et al
    BCG vaccination and multiple sclerosis risk: A Norwegian cohort study.
    Mult Scler. 2024 Feb 27:13524585241230440. doi: 10.1177/13524585241230440.
    PubMed     Abstract available
    
    
    
32. MILLER AE
    Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time for a change?
    Mult Scler. 2024 Feb 27:13524585241233999. doi: 10.1177/13524585241233999.
    PubMed     Abstract available
    
    
    
33. KRIEGER SC, Sinks S, Huang F, Steverson J, et al
    The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis.
    Mult Scler. 2024 Feb 26:13524585241232274. doi: 10.1177/13524585241232274.
    PubMed     Abstract available
    
    
    
34. BOAVENTURA M, Sastre-Garriga J, Rimkus CM, Rovira A, et al
    T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241233448. doi: 10.1177/13524585241233448.
    PubMed     Abstract available
    
    
    
35. EMMA C, Vesela P, Kay P, Huseyin H, et al
    Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
    Mult Scler. 2024 Feb 22:13524585241232277. doi: 10.1177/13524585241232277.
    PubMed     Abstract available
    
    
    
36. ERCAN MB, Kocer B, Altiparmak T, Arslan I, et al
    Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241231655. doi: 10.1177/13524585241231655.
    PubMed    
    
    
    
37. JALALEDDINI K, Bermel RA, Talente B, Weinstein D, et al
    A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241227372. doi: 10.1177/13524585241227372.
    PubMed     Abstract available
    
    
    
38. ROCCA MA, D'Amore G, Valsasina P, Tedone N, et al
    2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241231155. doi: 10.1177/13524585241231155.
    PubMed     Abstract available
    
    
    
39. ROVARIS M, Toselli E, Mendozzi L, Di Tella S, et al
    Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study.
    Mult Scler. 2024 Feb 19:13524585241230236. doi: 10.1177/13524585241230236.
    PubMed     Abstract available
    
    
    
40. HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
    A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial.
    Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
    PubMed     Abstract available
    
    
    
41. COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
    Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
    PubMed     Abstract available
    
    
    
42. PATEL S, Rafferty S, Aquino L, Chadha S, et al
    VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
    Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
    PubMed     Abstract available
    
    
    
43. KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
    Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
    PubMed     Abstract available
    
    
    
44. MOTL RW, Russell DI, Pilutti LA, Metse AP, et al
    Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report.
    Mult Scler. 2024 Feb 9:13524585241229332. doi: 10.1177/13524585241229332.
    PubMed     Abstract available
    
    
    
45. BELLUCCI G, Buscarinu MC, Renie R, Rinaldi V, et al
    Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach.
    Mult Scler. 2024 Feb 9:13524585241227119. doi: 10.1177/13524585241227119.
    PubMed     Abstract available
    
    
    
46. ZIAEI A, Solomon O, Casper TC, Waltz M, et al
    Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis.
    Mult Scler. 2024 Feb 9:13524585231224685. doi: 10.1177/13524585231224685.
    PubMed     Abstract available
    
    
    
47. GILMARTIN CG, Hoyle N, Garjani A, Dixon T, et al
    Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
    Mult Scler. 2024 Feb 7:13524585231225711. doi: 10.1177/13524585231225711.
    PubMed     Abstract available
    
    
    
48. MCGINLEY MP, Manouchehrinia A
    The landscape of multiple sclerosis registries: Strengths and limitations.
    Mult Scler. 2024 Feb 6:13524585241228746. doi: 10.1177/13524585241228746.
    PubMed    
    
    
    
49. VUKUSIC S, Bourre B, Casey R, Deiva K, et al
    The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics.
    Mult Scler. 2024;30:216-226.
    PubMed     Abstract available
    
    
    
50. GHAJARZADEH M, Fitzgerald KC, Mowry EM, Nourbakhsh B, et al
    Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS.
    Mult Scler. 2024;30:238-246.
    PubMed     Abstract available
    
    
    
51. SCHNEIDER R, Brand-Arzamendi K, Reynold Lim T, Lee LE, et al
    Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome.
    Mult Scler. 2024;30:156-165.
    PubMed     Abstract available
    
    
    
52. GONZALEZ CALDITO N, Graham EL, Grebenciucova E
    Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth.
    Mult Scler. 2024;30:272-274.
    PubMed     Abstract available
    
    
    
53. LANGDON D
    Neuropsychological assessment in MS is outdated and in need for innovation: NO.
    Mult Scler. 2024;30:152-153.
    PubMed    
    
    
    January 2024
54. NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
    Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
    Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
    PubMed     Abstract available
    
    
    
55. SWITAL M, Drouin J, Miranda S, Bakchine S, et al
    Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
    Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
    PubMed     Abstract available
    
    
    
56. MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
    White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study.
    Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
    PubMed     Abstract available
    
    
    
57. HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al
    Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
    Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938.
    PubMed     Abstract available
    
    
    
58. CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al
    Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
    Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138.
    PubMed     Abstract available
    
    
    
59. JEANTIN L, Januel E, Labauge P, Maillart E, et al
    COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
    Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149.
    PubMed     Abstract available
    
    
    
60. TENI FS, Machado A, Fink K, Gyllensten H, et al
    Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
    Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929.
    PubMed     Abstract available
    
    
    
61. VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al
    Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions.
    Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848.
    PubMed     Abstract available
    
    
    
62. TOOROP AA, Noteboom S, Steenwijk MD, Gravendeel JW, et al
    Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Mult Scler. 2024 Jan 18:13524585231225855. doi: 10.1177/13524585231225855.
    PubMed     Abstract available
    
    
    
63. DAS J, Rog DJ, Middleton R, Rodgers JW, et al
    University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register.
    Mult Scler. 2024 Jan 17:13524585231221411. doi: 10.1177/13524585231221411.
    PubMed     Abstract available
    
    
    
64. PORTACCIO E, Iaffaldano P
    Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggers.
    Mult Scler. 2024 Jan 11:13524585231224667. doi: 10.1177/13524585231224667.
    PubMed    
    
    
    
65. FRAMKE E, Thygesen LC, Malmborg M, Schou M, et al
    Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.
    Mult Scler. 2024 Jan 11:13524585231221415. doi: 10.1177/13524585231221415.
    PubMed     Abstract available
    
    
    
66. MOTYL J
    Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs.
    Mult Scler. 2024 Jan 9:13524585231221409. doi: 10.1177/13524585231221409.
    PubMed    
    
    
    
67. MORROW SA
    Response to letter to the editor "Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs".
    Mult Scler. 2024 Jan 9:13524585231221412. doi: 10.1177/13524585231221412.
    PubMed    
    
    
    
68. VENET M, Lepine A, Maarouf A, Biotti D, et al
    Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
    Mult Scler. 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069.
    PubMed     Abstract available
    
    
    
69. WEINSHENKER BG
    MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Commentary.
    Mult Scler. 2024;30:23-24.
    PubMed    
    
    
    
70. CARNERO CONTENTTI E, Wingerchuk DM
    MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes.
    Mult Scler. 2024;30:19-21.
    PubMed    
    
    
    
71. MARIGNIER R, Cree BA
    MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: No.
    Mult Scler. 2024;30:21-23.
    PubMed    
    
    
    
72. VAN LAETHEM D, Denissen S, Costers L, Descamps A, et al
    The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment.
    Mult Scler. 2024;30:121-130.
    PubMed     Abstract available
    
    
    
73. HUGOS CL, Joos SK, Perumean-Chaney SE, Cutter GR, et al
    Stretching is not essential for managing MS spasticity: A randomized controlled trial.
    Mult Scler. 2024;30:89-102.
    PubMed     Abstract available
    
    
    
74. DE GIER M, Beckerman H, Twisk JW, Knoop H, et al
    Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial.
    Mult Scler. 2024;30:71-79.
    PubMed     Abstract available
    
    
    
75. GUO RY, Wang WY, Huang JY, Jia Z, et al
    Deciphering prognostic indicators in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: An integrative review of demographic and laboratory factors.
    Mult Scler. 2024;30:7-15.
    PubMed     Abstract available
    
    
    
76. WRIGHT SL, Thompson AJ
    Managing patients with late-onset neutropenia during treatment with ocrelizumab.
    Mult Scler. 2024;30:134.
    PubMed    
    
    
    
77. KOCH-HENRIKSEN NI, Thygesen LC, Sorensen PS, Magyari M, et al
    Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS.
    Mult Scler. 2024;30:113-120.
    PubMed     Abstract available
    
    
    December 2023
78. PARCIAK T, Geys L, Helme A, van der Mei I, et al
    Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.
    Mult Scler. 2023 Dec 23:13524585231216004. doi: 10.1177/13524585231216004.
    PubMed     Abstract available
    
    
    
79. DOBSON R, Holden D, Vickaryous N, Bestwick J, et al
    A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
    Mult Scler. 2023 Dec 22:13524585231215268. doi: 10.1177/13524585231215268.
    PubMed     Abstract available
    
    
    
80. NAISMITH RT, Cohen JA, Bar-Or A, Comi G, et al
    Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
    Mult Scler. 2023 Dec 21:13524585231216854. doi: 10.1177/13524585231216854.
    PubMed     Abstract available
    
    
    
81. TAZZA F, Schiavi S, Leveraro E, Cellerino M, et al
    Clinical and radiological correlates of apathy in multiple sclerosis.
    Mult Scler. 2023 Dec 14:13524585231217918. doi: 10.1177/13524585231217918.
    PubMed     Abstract available
    
    
    
82. DABOUL L, O'Donnell CM, Amin M, Rodrigues P, et al
    A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
    Mult Scler. 2023 Dec 13:13524585231214360. doi: 10.1177/13524585231214360.
    PubMed     Abstract available
    
    
    
83. DALLA COSTA G, Nos C, Zabalza A, Buron M, et al
    A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
    Mult Scler. 2023 Dec 12:13524585231214362. doi: 10.1177/13524585231214362.
    PubMed     Abstract available
    
    
    
84. BRUCE JM, Cozart JS, Shook RP, Befort C, et al
    Modifying diet and exercise in multiple sclerosis (MoDEMS): A randomized controlled trial for behavioral weight loss in adults with multiple sclerosis and obesity.
    Mult Scler. 2023;29:1860-1871.
    PubMed     Abstract available
    
    
    
85. SACCO S, Virupakshaiah A, Papinutto N, Schoeps VA, et al
    Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease.
    Mult Scler. 2023;29:1736-1747.
    PubMed     Abstract available
    
    
    
86. LUBLIN FD
    Worsening MS-A reappraisal of how we characterize the MS disease course.
    Mult Scler. 2023;29:1699-1700.
    PubMed    
    
    
    
87. SAMADZADEH S, Olesen MN, Wirenfeldt M, Moller S, et al
    Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
    Mult Scler. 2023;29:1721-1735.
    PubMed     Abstract available
    
    
    
88. PROSCHMANN U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, et al
    Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
    Mult Scler. 2023;29:1849-1859.
    PubMed     Abstract available
    
    
    
89. MORROW SA, Weinstock ZL, Mirmosayyeb O, Conway D, et al
    Detecting isolated cognitive relapses in persons with MS.
    Mult Scler. 2023;29:1786-1794.
    PubMed     Abstract available
    
    
    
90. ENGELS D, Havla J, Forderreuther S, Kumpfel T, et al
    Therapy challenges for NMOSD in a patient with HIV.
    Mult Scler. 2023;29:1872-1875.
    PubMed     Abstract available
    
    
    November 2023
91. MATTIESING RM, Kramer E, Strijbis EM, Brouwer I, et al
    Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
    Mult Scler. 2023 Nov 29:13524585231212879. doi: 10.1177/13524585231212879.
    PubMed     Abstract available
    
    
    
92. ZHAO T, Taylor BV, Campbell JA, Palmer AJ, et al
    The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
    Mult Scler. 2023 Nov 24:13524585231213230. doi: 10.1177/13524585231213230.
    PubMed     Abstract available
    
    
    
93. MONTEIRO IR, Moccia M
    Mobile health interventions in multiple sclerosis: Bringing empowerment into clinical practice.
    Mult Scler. 2023 Nov 20:13524585231214879. doi: 10.1177/13524585231214879.
    PubMed    
    
    
    
94. CASTANO-AMORES C, Nieto-Gomez P
    The crossroads of multiple sclerosis and cancer: Urgent call for clinical direction.
    Mult Scler. 2023 Nov 20:13524585231214171. doi: 10.1177/13524585231214171.
    PubMed    
    
    
    
95. LADAKIS DC, Reyes-Mantilla MI, Gadani SP, Mace JW, et al
    Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Mult Scler. 2023 Nov 20:13524585231213164. doi: 10.1177/13524585231213164.
    PubMed     Abstract available
    
    
    
96. NIELSEN NM, Frisch M, Gortz S, Stenager E, et al
    Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study.
    Mult Scler. 2023 Nov 19:13524585231208310. doi: 10.1177/13524585231208310.
    PubMed     Abstract available
    
    
    
97. BROCHET B, Solari A, Lechner-Scott J, Piehl F, et al
    Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Mult Scler. 2023 Nov 18:13524585231205962. doi: 10.1177/13524585231205962.
    PubMed     Abstract available
    
    
    
98. NICHOLSON S, Russo AW, Brewer K, Bien H, et al
    The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
    Mult Scler. 2023 Nov 10:13524585231204710. doi: 10.1177/13524585231204710.
    PubMed     Abstract available
    
    
    
99. BOU RJEILY N, Fitzgerald KC, Mowry EM
    Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
    Mult Scler. 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311.
    PubMed     Abstract available
    
    
    
100. AMEZCUA L, Robers MV, Soneji D, Manouvakhova O, et al
     Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
     Mult Scler. 2023 Nov 9:13524585231209016. doi: 10.1177/13524585231209016.
     PubMed     Abstract available
     
     
     
101. VAN KEMPEN ZL, van Dam KP, Keijser JB, Stalman EW, et al
     Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
     Mult Scler. 2023 Nov 9:13524585231207761. doi: 10.1177/13524585231207761.
     PubMed     Abstract available
     
     
     
102. ZICCARDI S, Fuchs T, Dwyer MG, Zivadinov R, et al
     Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis.
     Mult Scler. 2023 Nov 9:13524585231208331. doi: 10.1177/13524585231208331.
     PubMed     Abstract available
     
     
     
103. FEINSTEIN A
     The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.
     Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178.
     PubMed    
     
     
     
104. CHASE E, Chen V, Martin K, Lane M, et al
     A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial.
     Mult Scler. 2023;29:1659-1675.
     PubMed     Abstract available
     
     
     
105. WEINSTOCK ZL, Jaworski M 3rd, Dwyer MG, Jakimovski D, et al
     Auditory Test of Processing Speed: Preliminary validation of a smartphone-based test of mental speed.
     Mult Scler. 2023;29:1646-1658.
     PubMed     Abstract available
     
     
     
106. WISHART M, Everest MR, Morrow SA, Rose J, et al
     Establishing the consistency of a voice recognition symbol digit modalities test analogue.
     Mult Scler. 2023;29:1676-1679.
     PubMed     Abstract available
     
     
     
107. BOCCIA VD, Saitta L, Inglese M, Lapucci C, et al
     Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient.
     Mult Scler. 2023;29:1688-1692.
     PubMed     Abstract available
     
     
     October 2023
108. ONTANEDA D, Amezcua L
     Re-thinking race and geography in multiple sclerosis.
     Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969.
     PubMed    
     
     
     
109. SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al
     Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
     Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708.
     PubMed     Abstract available
     
     
     
110. HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al
     Mobile health interventions in multiple sclerosis: A systematic review.
     Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089.
     PubMed     Abstract available
     
     
     
111. PORWAL MH, Obeidat AZ
     A closer look at reported colitis in association with multiple sclerosis treatments.
     Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964.
     PubMed    
     
     
     
112. LEARMONTH YC, P Herring M, Russell DI, Pilutti LA, et al
     Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.
     Mult Scler. 2023 Oct 26:13524585231204459. doi: 10.1177/13524585231204459.
     PubMed     Abstract available
     
     
     
113. RAMARI C, Awadia Z, Bansi J, Casey B, et al
     The MoxFo initiative - outcomes: Outcome measures in studies of exercise training in multiple sclerosis; scoping review of reviews and classification according to the ICF framework.
     Mult Scler. 2023 Oct 26:13524585231204451. doi: 10.1177/13524585231204451.
     PubMed     Abstract available
     
     
     
114. DALGAS U, Riemenschneider M, Gold SM, Kalron A, et al
     The MoXFo initiative - study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis.
     Mult Scler. 2023 Oct 26:13524585231204456. doi: 10.1177/13524585231204456.
     PubMed     Abstract available
     
     
     
115. MANSOUBI M, Learmonth YC, Mayo N, Collet J, et al
     The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research.
     Mult Scler. 2023 Oct 26:13524585231204460. doi: 10.1177/13524585231204460.
     PubMed     Abstract available
     
     
     
116. ROSENKRANZ SC, Ploughman M, Hvid LG, Zimmer P, et al
     The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies.
     Mult Scler. 2023 Oct 26:13524585231204453. doi: 10.1177/13524585231204453.
     PubMed     Abstract available
     
     
     
117. MOTL RW, Casey B, Learmonth YC, Latimer-Cheung A, et al
     The MoXFo initiative - adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research.
     Mult Scler. 2023 Oct 26:13524585231204446. doi: 10.1177/13524585231204446.
     PubMed     Abstract available
     
     
     
118. ZHANG Y, Atkinson J, Burd CE, Graves J, et al
     Biological aging in multiple sclerosis.
     Mult Scler. 2023 Oct 25:13524585231204122. doi: 10.1177/13524585231204122.
     PubMed     Abstract available
     
     
     
119. BEREK K, Hegen H, Auer M, Barket R, et al
     Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
     Mult Scler. 2023 Oct 18:13524585231201093. doi: 10.1177/13524585231201093.
     PubMed     Abstract available
     
     
     
120. KOCH MW, Moral E, Brieva L, Mostert J, et al
     Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
     Mult Scler. 2023 Oct 13:13524585231202320. doi: 10.1177/13524585231202320.
     PubMed     Abstract available
     
     
     
121. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
     Vaccination frequency in people newly diagnosed with multiple sclerosis.
     Mult Scler. 2023 Oct 13:13524585231199084. doi: 10.1177/13524585231199084.
     PubMed     Abstract available
     
     
     
122. REYES S, Otero-Romero S
     Rethinking vaccination in multiple sclerosis: The way forward.
     Mult Scler. 2023 Oct 3:13524585231204126. doi: 10.1177/13524585231204126.
     PubMed    
     
     
     
123. LAPUCCI C, Boccia VD, Sirito T, Cellerino M, et al
     Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
     Mult Scler. 2023 Oct 3:13524585231204121. doi: 10.1177/13524585231204121.
     PubMed     Abstract available
     
     
     
124. TIEPPO EMS, Silva GD, Silva TFFD, Araujo RS, et al
     Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process-Cohort study.
     Mult Scler. 2023 Oct 3:13524585231199323. doi: 10.1177/13524585231199323.
     PubMed     Abstract available
     
     
     
125. JACOBER SLS, Disanto G, Sacco R, Meng D, et al
     Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
     Mult Scler. 2023 Oct 3:13524585231199820. doi: 10.1177/13524585231199820.
     PubMed     Abstract available
     
     
     
126. UHER T, Adzima A, Srpova B, Noskova L, et al
     Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
127. WU Y, Geraldes R, Jurynczyk M, Palace J, et al
     Double-negative neuromyelitis optica spectrum disorder.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
128. THOMPSON AJ, Moccia M, Amato MP, Calabresi PA, et al
     Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     September 2023
129. ANDERSON JR, Fitzgerald KC, Murrough JW, Katz Sand IB, et al
     Depression symptoms and cognition in multiple sclerosis: Longitudinal evidence of a specific link to executive control.
     Mult Scler. 2023 Sep 29:13524585231198746. doi: 10.1177/13524585231198746.
     PubMed     Abstract available
     
     
     
130. CERDA-FUERTES N, Stoessel M, Mickeliunas G, Pless S, et al
     Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
     Mult Scler. 2023 Sep 29:13524585231198760. doi: 10.1177/13524585231198760.
     PubMed     Abstract available
     
     
     
131. VERCELLINO M, Costantini G, Cogoni M, Lequio L, et al
     Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
     Mult Scler. 2023 Sep 23:13524585231199031. doi: 10.1177/13524585231199031.
     PubMed     Abstract available
     
     
     
132. FREEDMAN DE, Krysko KM, Feinstein A
     Intimate partner violence and multiple sclerosis.
     Mult Scler. 2023 Sep 21:13524585231197926. doi: 10.1177/13524585231197926.
     PubMed     Abstract available
     
     
     
133. CARVAJAL R, Tur C, Martinez-Gomez X, Bollo L, et al
     A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
     Mult Scler. 2023 Sep 20:13524585231200303. doi: 10.1177/13524585231200303.
     PubMed     Abstract available
     
     
     
134. MORALES-RODRIGUEZ D, Anderson A, Nylander A, Hsu S, et al
     Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis.
     Mult Scler. 2023 Sep 16:13524585231197056. doi: 10.1177/13524585231197056.
     PubMed     Abstract available
     
     
     
135. KRAJNC N, Schmidbauer V, Leinkauf J, Haider L, et al
     Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis.
     Mult Scler. 2023 Sep 15:13524585231197954. doi: 10.1177/13524585231197954.
     PubMed     Abstract available
     
     
     
136. BOSE G, Healy BC, Barro C, Moreira Ferreira VF, et al
     Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis.
     Mult Scler. 2023 Sep 15:13524585231198751. doi: 10.1177/13524585231198751.
     PubMed     Abstract available
     
     
     
137. MARTIN SJ, Brand-Arzamendi K, Saab G, Muccilli A, et al
     GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis.
     Mult Scler. 2023 Sep 12:13524585231195861. doi: 10.1177/13524585231195861.
     PubMed     Abstract available
     
     
     
138. MOGHAVEM N, Castaneda GDR, Chatfield AJ, Amezcua L, et al
     The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review.
     Mult Scler. 2023 Sep 12:13524585231197275. doi: 10.1177/13524585231197275.
     PubMed     Abstract available
     
     
     
139. WANG Y, Bou Rjeily N, Koshorek J, Grkovski R, et al
     Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States.
     Mult Scler. 2023 Sep 12:13524585231196795. doi: 10.1177/13524585231196795.
     PubMed     Abstract available
     
     
     
140. BRUNO A, Buttari F, Dolcetti E, Azzolini F, et al
     Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
     Mult Scler. 2023 Sep 12:13524585231197928. doi: 10.1177/13524585231197928.
     PubMed     Abstract available
     
     
     
141. HAUSER SL, Zielman R, Das Gupta A, Xi J, et al
     Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
     Mult Scler. 2023 Sep 11:13524585231195346. doi: 10.1177/13524585231195346.
     PubMed     Abstract available
     
     
     
142. DEJONGE SR, DuBose NG, Pilutti LA, Motl RW, et al
     Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic fitness account for group differences?
     Mult Scler. 2023 Sep 11:13524585231199030. doi: 10.1177/13524585231199030.
     PubMed     Abstract available
     
     
     
143. GABRIELLI M, Verderio C
     Exosomal profiling should be used to monitor disease activity in MS patients: Commentary.
     Mult Scler. 2023 Sep 7:13524585231195858. doi: 10.1177/13524585231195858.
     PubMed    
     
     
     
144. DELTOMBE M, van Pesch V
     Exosomal profiling should be used to monitor disease activity in MS patients: No.
     Mult Scler. 2023 Sep 7:13524585231195859. doi: 10.1177/13524585231195859.
     PubMed    
     
     
     
145. MYCKO MP
     Exosomal profiling should be used to monitor disease activity in MS patients: Yes.
     Mult Scler. 2023 Sep 7:13524585231195860. doi: 10.1177/13524585231195860.
     PubMed    
     
     
     
146. CARNERO CONTENTTI E
     Rectifying global inequities in neuromyelitis optica diagnosis and treatment: A critical view from Latin America.
     Mult Scler. 2023;29:1347-1348.
     PubMed    
     
     
     
147. BERHANU D, Leal Rato M, Messina S, Leite MI, et al
     The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
     Mult Scler. 2023;29:1250-1256.
     PubMed     Abstract available
     
     
     
148. CARNERO CONTENTTI E, Lopez PA, Tkachuk V, Vrech C, et al
     Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting.
     Mult Scler. 2023;29:1240-1249.
     PubMed     Abstract available
     
     
     August 2023
149. HARDY TA
     Pseudocystic demyelination in multiple sclerosis.
     Mult Scler. 2023 Aug 25:13524585231193365. doi: 10.1177/13524585231193365.
     PubMed    
     
     
     
150. CLUSE F, Fenouil T, Vukusic S, Ducray F, et al
     Pseudocystic inflammatory demyelinating lesions in multiple sclerosis: A clinical, radiological, and pathological description.
     Mult Scler. 2023 Aug 25:13524585231193345. doi: 10.1177/13524585231193345.
     PubMed     Abstract available
     
     
     
151. BAR-OR A, Cross AH, Cunningham AL, Hyvert Y, et al
     Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
     Mult Scler. 2023 Aug 25:13524585231192460. doi: 10.1177/13524585231192460.
     PubMed     Abstract available
     
     
     
152. RAIMO S, Santangelo G, Cropano M, Gaita M, et al
     Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis.
     Mult Scler. 2023 Aug 21:13524585231192469. doi: 10.1177/13524585231192469.
     PubMed     Abstract available
     
     
     
153. BALSHI A, Saart E, Pandeya S, Dempsey J, et al
     High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate.
     Mult Scler. 2023 Aug 12:13524585231189641. doi: 10.1177/13524585231189641.
     PubMed     Abstract available
     
     
     
154. FAN JH, Alexander J, Poole S, Wijangco J, et al
     Characteristics of multiple sclerosis and demyelinating disease in an Asian American population.
     Mult Scler. 2023 Aug 7:13524585231188486. doi: 10.1177/13524585231188486.
     PubMed     Abstract available
     
     
     
155. MARRIE RA, Bernstein CN, Dolovich C, Bolton JM, et al
     Within-person fluctuations over three years in depression, anxiety, fatigue, and health-related quality of life in multiple sclerosis.
     Mult Scler. 2023 Aug 3:13524585231190771. doi: 10.1177/13524585231190771.
     PubMed     Abstract available
     
     
     
156. NAKAMURA K, Zheng Y, Mahajan KR, Cohen JA, et al
     Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
     Mult Scler. 2023 Aug 3:13524585231187289. doi: 10.1177/13524585231187289.
     PubMed     Abstract available
     
     
     
157. WESSELS MH, Van Lierop ZY, Noteboom S, Strijbis EM, et al
     Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
     Mult Scler. 2023 Aug 2:13524585231188625. doi: 10.1177/13524585231188625.
     PubMed     Abstract available
     
     
     
158. TAYLOR LA, Mhizha-Murira JR, Law G, Evangelou N, et al
     Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis.
     Mult Scler. 2023 Aug 1:13524585231189470. doi: 10.1177/13524585231189470.
     PubMed     Abstract available
     
     
     
159. COTE SE, Wagshul ME, Foley FW, Lipton ML, et al
     Caudate volume and symptoms of apathy in older adults with multiple sclerosis.
     Mult Scler. 2023 Aug 1:13524585231188096. doi: 10.1177/13524585231188096.
     PubMed     Abstract available
     
     
     
160. GRAY E, Amjad A, Robertson J, Beveridge J, et al
     Enhancing involvement of people with multiple sclerosis in clinical trial design.
     Mult Scler. 2023;29:1162-1173.
     PubMed     Abstract available
     
     
     
161. SORMANI MP, Chataway J, Kent DM, Marrie RA, et al
     Assessing heterogeneity of treatment effect in multiple sclerosis trials.
     Mult Scler. 2023;29:1158-1161.
     PubMed     Abstract available
     
     
     
162. MARRIE RA, Sormani MP, Apap Mangion S, Bovis F, et al
     Improving the efficiency of clinical trials in multiple sclerosis.
     Mult Scler. 2023;29:1136-1148.
     PubMed     Abstract available
     
     
     
163. FINLAYSON M, Al-Mashita L, Sandhu R
     Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: A scoping review.
     Mult Scler. 2023;29:1149-1157.
     PubMed     Abstract available
     
     
     
164. MARRIE RA, Chataway J, Bierer BE, Finlayson M, et al
     Enhancing diversity of clinical trial populations in multiple sclerosis.
     Mult Scler. 2023;29:1174-1185.
     PubMed     Abstract available
     
     
     
165. FINLAYSON M, Feys P, Dalgas U, Kos D, et al
     Intermediate outcomes for clinical trials of multiple sclerosis rehabilitation interventions: Conceptual and practical considerations.
     Mult Scler. 2023;29:1186-1194.
     PubMed     Abstract available
     
     
     
166. GIOVANNONI G
     Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.
     Mult Scler. 2023;29:1068-1069.
     PubMed    
     
     
     
167. STRIJBIS E, Koch MW, de Jong BA
     Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.
     Mult Scler. 2023;29:1066-1067.
     PubMed    
     
     
     
168. GOVEROVER Y, Chiaravalloti N
     Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
     Mult Scler. 2023;29:1064-1065.
     PubMed    
     
     
     
169. LOTAN I, Chen JJ, Hacohen Y, Abdel-Mannan O, et al
     Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease.
     Mult Scler. 2023;29:1080-1089.
     PubMed     Abstract available
     
     
     
170. COHEN M, Thomel-Rocchi O, Siva A, Okuda DT, et al
     Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
     Mult Scler. 2023;29:1099-1106.
     PubMed     Abstract available
     
     
     July 2023
171. CAVALLA P, Vercellino M
     May Mediterranean diet contribute to reduce risk of multiple sclerosis?
     Mult Scler. 2023 Jul 29:13524585231190342. doi: 10.1177/13524585231190342.
     PubMed    
     
     
     
172. GUNZLER DD, De Nadai AS, Miller DM, Ontaneda D, et al
     Long-term trajectories of ambulatory impairment in multiple sclerosis.
     Mult Scler. 2023 Jul 28:13524585231187521. doi: 10.1177/13524585231187521.
     PubMed     Abstract available
     
     
     
173. JAWORSKI MG 3RD, Gillies JK, Youngs M, Wojcik C, et al
     Predicting employment deterioration with the Processing Speed Test (PST) and SDMT in multiple sclerosis.
     Mult Scler. 2023 Jul 28:13524585231187283. doi: 10.1177/13524585231187283.
     PubMed     Abstract available
     
     
     
174. GOVEROVER Y, Amber S, John D
     Assessing everyday functional activity in cognitively impaired people with multiple sclerosis: The use of Actual Reality(TM).
     Mult Scler. 2023 Jul 26:13524585231185048. doi: 10.1177/13524585231185048.
     PubMed     Abstract available
     
     
     
175. DE GIER M, Beckerman H, Twisk J, Knoop H, et al
     Blended versus face-to-face cognitive behavioural therapy for severe fatigue in patients with multiple sclerosis: A non-inferiority RCT.
     Mult Scler. 2023 Jul 25:13524585231185462. doi: 10.1177/13524585231185462.
     PubMed     Abstract available
     
     
     
176. TITBALL RW, Lewis N, Nicholas R
     Is Clostridium perfringens epsilon toxin associated with multiple sclerosis?
     Mult Scler. 2023 Jul 22:13524585231186899. doi: 10.1177/13524585231186899.
     PubMed     Abstract available
     
     
     
177. COHEN JA
     Commentary: Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol (in press).
     Mult Scler. 2023 Jul 20:13524585231188097. doi: 10.1177/13524585231188097.
     PubMed    
     
     
     
178. BOLES GS, Hillert J, Ramanujam R, Westerlind H, et al
     The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study.
     Mult Scler. 2023 Jul 12:13524585231185258. doi: 10.1177/13524585231185258.
     PubMed     Abstract available
     
     
     
179. ORLANDO CM, Perez CA, Agyei P, Elsehety M, et al
     Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis.
     Mult Scler. 2023 Jul 12:13524585231185046. doi: 10.1177/13524585231185046.
     PubMed     Abstract available
     
     
     
180. SIPILA JO, Viitala M, Hanninen A, Soilu-Hanninen M, et al
     Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis.
     Mult Scler. 2023 Jul 10:13524585231185045. doi: 10.1177/13524585231185045.
     PubMed     Abstract available
     
     
     
181. NEYAL N, Keegan BM, Kantarci OH, Zeydan B, et al
     Coexistence of multiple sclerosis and spinocerebellar ataxia type-8.
     Mult Scler. 2023 Jul 3:13524585231180549. doi: 10.1177/13524585231180549.
     PubMed     Abstract available
     
     
     
182. KLINEOVA S, Farber RS, DeAngelis T, Leung T, et al
     Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
     Mult Scler. 2023;29:990-1000.
     PubMed     Abstract available
     
     
     
183. ZALOUM SA, Wood CH, Tank P, Upcott M, et al
     Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
     Mult Scler. 2023;29:979-989.
     PubMed     Abstract available
     
     
     
184. MATEEN FJ
     Rectifying global inequities in neuromyelitis optica diagnosis and treatment.
     Mult Scler. 2023;29:932-935.
     PubMed     Abstract available
     
     
     
185. WEINSHENKER BG, Wingerchuk DM, Green AJ, Bennett JL, et al
     Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
     Mult Scler. 2023;29:945-955.
     PubMed     Abstract available
     
     
     
186. REEVES JA, Weinstock Z, Zivadinov R, Dwyer MG, et al
     Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse.
     Mult Scler. 2023;29:1033-1038.
     PubMed     Abstract available
     
     
     
187. HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
     A taxonomic approach to cognitive diagnostics is viable and achievable in MS.
     Mult Scler. 2023;29:1040-1042.
     PubMed    
     
     
     June 2023
188. HE AH, Manouchehrinia A, Glaser A, Ciccarelli O, et al
     Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis.
     Mult Scler. 2023 Jun 30:13524585231181578. doi: 10.1177/13524585231181578.
     PubMed     Abstract available
     
     
     
189. ALFREDSSON L, Olsson T, Hedstrom AK
     Inverse association between Mediterranean diet and risk of multiple sclerosis.
     Mult Scler. 2023 Jun 27:13524585231181841. doi: 10.1177/13524585231181841.
     PubMed     Abstract available
     
     
     
190. JIANG X, Shen C, Teunissen CE, Wessels M, et al
     Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
     Mult Scler. 2023 Jun 15:13524585231176732. doi: 10.1177/13524585231176732.
     PubMed     Abstract available
     
     
     
191. SMOOT K, Marginean H, Gervasi-Follmar T, Chen C, et al
     Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
     Mult Scler. 2023 Jun 15:13524585231175284. doi: 10.1177/13524585231175284.
     PubMed     Abstract available
     
     
     
192. OTERO-ROMERO S, Lebrun-Frenay C, Reyes S, Amato MP, et al
     ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
     Mult Scler. 2023 Jun 9:13524585231168043. doi: 10.1177/13524585231168043.
     PubMed     Abstract available
     
     
     
193. NYLANDER AN, Singh J, Poole S, Anderson A, et al
     Clinical course of multiple sclerosis and patient experiences during breast cancer treatment.
     Mult Scler. 2023 Jun 8:13524585231175975. doi: 10.1177/13524585231175975.
     PubMed     Abstract available
     
     
     
194. DELAVAL S, Dequirez PL, Hentzen C, Baron M, et al
     Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee o
     Mult Scler. 2023 Jun 2:13524585231174580. doi: 10.1177/13524585231174580.
     PubMed     Abstract available
     
     
     
195. LUBLIN FD, Krieger SC
     MS becomes a treatable disease: 30 years later.
     Mult Scler. 2023;29:789-792.
     PubMed     Abstract available
     
     
     
196. KIM NN, Abdel-Mannan O, Davidson J, Du Pre P, et al
     Leigh syndrome mimicking neuromyelitis optica spectrum disorder (NMOSD).
     Mult Scler. 2023;29:889-892.
     PubMed     Abstract available
     
     
     
197. JURYNCZYK M
     Mitochondrial diseases mimicking NMOSD.
     Mult Scler. 2023;29:897-898.
     PubMed    
     
     
     
198. WILKINS SR, Yu AW, Steigerwald C, Tanji K, et al
     Two cases of MT-ND5-related mitochondrial disorder misdiagnosed as seronegative neuromyelitis optica spectrum disorder.
     Mult Scler. 2023;29:892-897.
     PubMed     Abstract available
     
     
     
199. REDENBAUGH V, Chia NH, Cacciaguerra L, McCombe JA, et al
     Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
     Mult Scler. 2023;29:799-808.
     PubMed     Abstract available
     
     
     
200. LEBRUN-FRENAY C, Okuda DT
     Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes.
     Mult Scler. 2023;29:793-795.
     PubMed    
     
     
     
201. INGLESE M, Amato MP
     Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary.
     Mult Scler. 2023;29:797-798.
     PubMed    
     
     
     
202. SMETS I
     Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated - NO.
     Mult Scler. 2023;29:795-797.
     PubMed    
     
     
     
203. HUMMERT MW, Stern C, Paul F, Duchow A, et al
     Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
     Mult Scler. 2023;29:819-831.
     PubMed     Abstract available
     
     
     May 2023
204. BANWELL B
     Pediatric multiple sclerosis: The 2022 ECTRIMS lecture.
     Mult Scler. 2023 May 30:13524585231171047. doi: 10.1177/13524585231171047.
     PubMed     Abstract available
     
     
     
205. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
     Sars-CoV2 infection in pregnant women with multiple sclerosis.
     Mult Scler. 2023 May 26:13524585231176174. doi: 10.1177/13524585231176174.
     PubMed     Abstract available
     
     
     
206. ALSHEHRI E, Cohen JA, Ontaneda D, Nakamura K, et al
     The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
     Mult Scler. 2023 May 19:13524585231172490. doi: 10.1177/13524585231172490.
     PubMed     Abstract available
     
     
     
207. VIRUPAKSHAIAH A, Ladakis DC, Nourbakhsh B, Bhargava P, et al
     Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.
     Mult Scler. 2023 May 18:13524585231171517. doi: 10.1177/13524585231171517.
     PubMed     Abstract available
     
     
     
208. VALENTINE TR, Kratz AL, Kaplish N, Chervin RD, et al
     Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains.
     Mult Scler. 2023 May 17:13524585231169465. doi: 10.1177/13524585231169465.
     PubMed     Abstract available
     
     
     
209. CAPUANO R, Prosperini L, Altieri M, Lorefice L, et al
     Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
     Mult Scler. 2023 May 11:13524585231167515. doi: 10.1177/13524585231167515.
     PubMed     Abstract available
     
     
     
210. SAUL AM, Taylor BV, Blizzard L, Simpson-Yap S, et al
     A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study.
     Mult Scler. 2023 May 6:13524585231167739. doi: 10.1177/13524585231167739.
     PubMed     Abstract available
     
     
     
211. KOLIND S, Gaetano L, Assemlal HE, Bernasconi C, et al
     Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
     Mult Scler. 2023;29:741-747.
     PubMed     Abstract available
     
     
     
212. SCHWAKE C, Pakeerathan T, Kleiter I, Ringelstein M, et al
     Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies.
     Mult Scler. 2023;29:757-761.
     PubMed     Abstract available
     
     
     April 2023
213. MARRIE RA
     The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward.
     Mult Scler. 2023 Apr 26:13524585231167740. doi: 10.1177/13524585231167740.
     PubMed     Abstract available
     
     
     
214. FINK K, Gorczyca A, Alping P, Englund S, et al
     Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study.
     Mult Scler. 2023 Apr 18:13524585231161492. doi: 10.1177/13524585231161492.
     PubMed     Abstract available
     
     
     
215. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Michaux K, et al
     Employment status, productivity loss, and associated factors among people with multiple sclerosis.
     Mult Scler. 2023 Apr 15:13524585231164295. doi: 10.1177/13524585231164295.
     PubMed     Abstract available
     
     
     
216. ELLIOTT C, Rudko DA, Arnold DL, Fetco D, et al
     Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
     Mult Scler. 2023 Apr 10:13524585231162262. doi: 10.1177/13524585231162262.
     PubMed     Abstract available
     
     
     
217. PALLADINO R, Marrie RA, Majeed A, Chataway J, et al
     Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.
     Mult Scler. 2023 Apr 7:13524585231164296. doi: 10.1177/13524585231164296.
     PubMed     Abstract available
     
     
     
218. GIOVANNONI G, Boyko A, Correale J, Edan G, et al
     Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
     Mult Scler. 2023 Apr 3:13524585231161494. doi: 10.1177/13524585231161494.
     PubMed     Abstract available
     
     
     
219. SATYANARAYAN S, Cutter G, Krieger S, Cofield S, et al
     The impact of relapse definition and measures of durability on MS clinical trial outcomes.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
220. WITTAYER M, Weber CE, Kittel M, Platten M, et al
     Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
221. NAKAMURA M, Ogawa R, Fujimori J, Uzawa A, et al
     Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
222. KLISTORNER S, Van der Walt A, Barnett MH, Butzkueven H, et al
     Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
223. LEE S, Muccilli A, Schneider R, Selchen D, et al
     Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
224. ROTSTEIN DL, Wolfson C, Carruthers R, Freedman MS, et al
     A national case-control study investigating demographic and environmental factors associated with NMOSD.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
225. TOHYAMA S, Oh J, Timm M, Cheng JC, et al
     Should trigeminal neuralgia be considered a clinically isolated syndrome?
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
226. CARNERO CONTENTTI E, Correale J
     Association between infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
227. ROMAN S
     A journey with no roadmap-The need for validated criteria of the MS prodrome.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     March 2023
228. OTTO C, Schwarz T, Jeworowski LM, Schmidt ML, et al
     Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.
     Mult Scler. 2023 Mar 28:13524585231161253. doi: 10.1177/13524585231161253.
     PubMed     Abstract available
     
     
     
229. SIMON S, Nauta IM, Hillebrand A, Schoonheim MM, et al
     Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.
     Mult Scler. 2023 Mar 25:13524585231159817. doi: 10.1177/13524585231159817.
     PubMed     Abstract available
     
     
     
230. GHEZZI A, Neuteboom RF
     The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized T
     Mult Scler. 2023 Mar 23:13524585231161148. doi: 10.1177/13524585231161148.
     PubMed    
     
     
     
231. SCHREINER T, Wilson-Murphy M, Mendelt-Tillema J, Waltz M, et al
     Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.
     Mult Scler. 2023 Mar 23:13524585231151948. doi: 10.1177/13524585231151948.
     PubMed     Abstract available
     
     
     
232. MARRODAN M, Piedrabuena MA, Gaitan MI, Fiol MP, et al
     Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina.
     Mult Scler. 2023 Mar 21:13524585231157276. doi: 10.1177/13524585231157276.
     PubMed     Abstract available
     
     
     
233. MOTL RW, Kidwell-Chandler A, Sandroff BM, Pilutti LA, et al
     Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project.
     Mult Scler. 2023;29:415-426.
     PubMed     Abstract available
     
     
     
234. KUHLE J, Chitnis T, Banwell B, Tardieu M, et al
     Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
     Mult Scler. 2023;29:385-394.
     PubMed     Abstract available
     
     
     
235. TOOROP AA, Steenhuis M, Loeff FC, Weijers SS, et al
     Fingerprick blood samples to measure serum natalizumab concentrations.
     Mult Scler. 2023;29:457-460.
     PubMed     Abstract available
     
     
     February 2023
236. DARUWALLA C, Shaygannejad V, Ozakbas S, Havrdova EK, et al
     Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
     Mult Scler. 2023 Feb 27:13524585231151951. doi: 10.1177/13524585231151951.
     PubMed     Abstract available
     
     
     
237. SANDRY J, Levy S, Sumowski JF
     Psychometrically valid interpretation of cognitive assessments is a prerequisite for classification of cognitive phenotypes in multiple sclerosis.
     Mult Scler. 2023 Feb 21:13524585231157000. doi: 10.1177/13524585231157000.
     PubMed    
     
     
     
238. ROOS I, Diouf I, Sharmin S, Horakova D, et al
     Comparative effectiveness in multiple sclerosis: A methodological comparison.
     Mult Scler. 2023 Feb 19:13524585231151394. doi: 10.1177/13524585231151394.
     PubMed     Abstract available
     
     
     
239. DOLCETTI E, Bruno A, Azzolini F, Gilio L, et al
     Genetic regulation of IL-8 influences disease presentation of multiple sclerosis.
     Mult Scler. 2023 Feb 19:13524585231155049. doi: 10.1177/13524585231155049.
     PubMed     Abstract available
     
     
     
240. DANG YL, Yong VT, Sharmin S, Perucca P, et al
     Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis.
     Mult Scler. 2023 Feb 19:13524585231151400. doi: 10.1177/13524585231151400.
     PubMed     Abstract available
     
     
     
241. MANOUCHEHRINIA A, Larsson H, Karim ME, Lycke J, et al
     Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
     Mult Scler. 2023 Feb 15:13524585231153992. doi: 10.1177/13524585231153992.
     PubMed     Abstract available
     
     
     
242. HORTON MK, Shim JE, Wallace A, Graves JS, et al
     Rare and low-frequency coding genetic variants contribute to pediatric-onset multiple sclerosis.
     Mult Scler. 2023 Feb 8:13524585221150736. doi: 10.1177/13524585221150736.
     PubMed     Abstract available
     
     
     
243. LAM KH, Bucur IG, van Oirschot P, de Graaf F, et al
     Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis.
     Mult Scler. 2023 Feb 8:13524585231152433. doi: 10.1177/13524585231152433.
     PubMed     Abstract available
     
     
     
244. IYER P, Wiles K, Ismail A, Nanda S, et al
     Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus.
     Mult Scler. 2023 Feb 5:13524585221148094. doi: 10.1177/13524585221148094.
     PubMed     Abstract available
     
     
     
245. STEFANOU MI, Palaiodimou L, Theodorou A, Christodoulou MV, et al
     Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
     Mult Scler. 2023 Feb 1:13524585221150881. doi: 10.1177/13524585221150881.
     PubMed     Abstract available
     
     
     
246. CARNERO CONTENTTI E, Lopez PA, Criniti J, Alonso R, et al
     Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors.
     Mult Scler. 2023;29:277-286.
     PubMed     Abstract available
     
     
     
247. BRENTON JN, Piccio L
     Strengthening the link: Diet quality and disability in MS.
     Mult Scler. 2023;29:157-159.
     PubMed    
     
     
     January 2023
248. CHIA NH, Redenbaugh V, Chen JJ, Pittock SJ, et al
     Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis.
     Mult Scler. 2023 Jan 24:13524585221150743. doi: 10.1177/13524585221150743.
     PubMed     Abstract available
     
     
     
249. HU C, Dewey BE, Mowry EM, Fitzgerald KC, et al
     Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort.
     Mult Scler. 2023 Jan 24:13524585221148144. doi: 10.1177/13524585221148144.
     PubMed     Abstract available
     
     
     
250. SADOVNICK D, Criscuoli M, Yee I, Carruthers R, et al
     The Canadian Multiple Sclerosis Pregnancy Study: First-trimester miscarriages in women with multiple sclerosis.
     Mult Scler. 2023 Jan 22:13524585221146270. doi: 10.1177/13524585221146270.
     PubMed     Abstract available
     
     
     
251. ABBADESSA G, Miele G, Maida E, Vanore E, et al
     Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis.
     Mult Scler. 2023 Jan 22:13524585221147635. doi: 10.1177/13524585221147635.
     PubMed     Abstract available
     
     
     
252. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
     Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life.
     Mult Scler. 2023 Jan 19:13524585221144413. doi: 10.1177/13524585221144413.
     PubMed     Abstract available
     
     
     
253. ANDERSON J, Sumowski JF
     Towards a phenotypic understanding of multiple sclerosis depression.
     Mult Scler. 2023 Jan 12:13524585221148143. doi: 10.1177/13524585221148143.
     PubMed    
     
     
     
254. BRALEY TJ, Shieu MM, Zaheed AB, Dunietz GL, et al
     Pathways between multiple sclerosis, sleep disorders, and cognitive function: Longitudinal findings from The Nurses' Health Study.
     Mult Scler. 2023 Jan 12:13524585221144215. doi: 10.1177/13524585221144215.
     PubMed     Abstract available
     
     
     
255. GRECH LB
     Addressing me in the context of my disease: Why it is so complicated.
     Mult Scler. 2023;29:8-10.
     PubMed     Abstract available
     
     
     
256. PESTCHANKER C, Diaconchuk M, Lopez P, Montano MR, et al
     Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.
     Mult Scler. 2023;29:150-153.
     PubMed     Abstract available
     
     
     
257. KRUPP LB, Waubant E, Waltz M, Casper TC, et al
     A new look at cognitive functioning in pediatric MS.
     Mult Scler. 2023;29:140-149.
     PubMed     Abstract available
     
     
     
258. FRIEDLI C, Wagner F, Hammer HN, Kamber N, et al
     Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
     Mult Scler. 2023;29:63-73.
     PubMed     Abstract available
     
     
     
259. JACKSON-TARLTON CS, Flanagan EP, Messina SA, Barakat B, et al
     Progressive motor impairment from "critical" demyelinating lesions of the cervicomedullary junction.
     Mult Scler. 2023;29:74-80.
     PubMed     Abstract available
     
     
     December 2022
260. BLOCK VJ, Cheng S, Juwono J, Cuneo R, et al
     Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis.
     Mult Scler. 2022 Dec 27:13524585221143726. doi: 10.1177/13524585221143726.
     PubMed     Abstract available
     
     
     
261. FOX RJ, Tervonen T, Phillips-Beyer A, Sidorenko T, et al
     The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
     Mult Scler. 2022 Dec 22:13524585221140270. doi: 10.1177/13524585221140270.
     PubMed     Abstract available
     
     
     
262. TSAGKAS C, Huck-Horvath A, Cagol A, Haas T, et al
     Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
     Mult Scler. 2022 Dec 22:13524585221139152. doi: 10.1177/13524585221139152.
     PubMed     Abstract available
     
     
     
263. JAKIMOVSKI D, Kavak KS, Zakalik K, Coetzee T, et al
     Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
     Mult Scler. 2022 Dec 22:13524585221140271. doi: 10.1177/13524585221140271.
     PubMed     Abstract available
     
     
     
264. LONGONI G, Martinez Chavez E, Young K, Brown RA, et al
     Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis.
     Mult Scler. 2022 Dec 22:13524585221137500. doi: 10.1177/13524585221137500.
     PubMed     Abstract available
     
     
     
265. KRAJNC N, Dal-Bianco A, Leutmezer F, Kasprian G, et al
     Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis.
     Mult Scler. 2022 Dec 20:13524585221138486. doi: 10.1177/13524585221138486.
     PubMed     Abstract available
     
     
     
266. HEGEN H, Arrambide G, Gnanapavan S, Kaplan B, et al
     Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.
     Mult Scler. 2022 Dec 17:13524585221134217. doi: 10.1177/13524585221134217.
     PubMed     Abstract available
     
     
     
267. CALVI A, Clarke MA, Prados F, Chard D, et al
     Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
     Mult Scler. 2022 Dec 14:13524585221141964. doi: 10.1177/13524585221141964.
     PubMed     Abstract available
     
     
     
268. SABATHE C, Casey R, Vukusic S, Leray E, et al
     Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
     Mult Scler. 2022 Dec 14:13524585221139156. doi: 10.1177/13524585221139156.
     PubMed     Abstract available
     
     
     
269. DE MEO E, Portaccio E
     It is time to define cognitive phenotypes in multiple sclerosis.
     Mult Scler. 2022 Dec 14:13524585221141263. doi: 10.1177/13524585221141263.
     PubMed    
     
     
     
270. JOKUBAITIS VG
     A role for HLA in mediating long-term multiple sclerosis outcomes?
     Mult Scler. 2022 Dec 14:13524585221139767. doi: 10.1177/13524585221139767.
     PubMed    
     
     
     
271. BOCCIA VD, Lapucci C, Cellerino M, Tazza F, et al
     Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study.
     Mult Scler. 2022 Dec 13:13524585221142319. doi: 10.1177/13524585221142319.
     PubMed     Abstract available
     
     
     
272. ABDEL-MANNAN O, Ciccarelli O
     Is the central vein sign a useful diagnostic marker for paediatric-onset multiple sclerosis?
     Mult Scler. 2022 Dec 13:13524585221142318. doi: 10.1177/13524585221142318.
     PubMed    
     
     
     
273. OKUDA DT, Stanley T, McCreary M, Smith A, et al
     Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry.
     Mult Scler. 2022 Dec 12:13524585221139575. doi: 10.1177/13524585221139575.
     PubMed     Abstract available
     
     
     
274. KOSSOWSKI B, Kong Y, Klimiec-Moskal E, Emir U, et al
     Relapsing antibody-negative patients with features of neuromyelitis optica spectrum disorders: Differences in N-acetylaspartate level in the cervical spinal cord indicate distinct underlying processes.
     Mult Scler. 2022;28:2221-2230.
     PubMed     Abstract available
     
     
     
275. HEGEN H, Walde J, Berek K, Arrambide G, et al
     Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.
     Mult Scler. 2022 Dec 1:13524585221134213. doi: 10.1177/13524585221134213.
     PubMed     Abstract available
     
     
     November 2022
276. MOTTE J, Gold R
     Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
     Mult Scler. 2022 Nov 30:13524585221137275. doi: 10.1177/13524585221137275.
     PubMed    
     
     
     
277. BARRITT AW, Das E, Morley N, Seymour M, et al
     Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
     Mult Scler. 2022 Nov 30:13524585221137279. doi: 10.1177/13524585221137279.
     PubMed     Abstract available
     
     
     
278. MORADI N, Sharmin S, Malpas CB, Shaygannejad V, et al
     External validation of a clinical prediction model in multiple sclerosis.
     Mult Scler. 2022 Nov 30:13524585221136036. doi: 10.1177/13524585221136036.
     PubMed     Abstract available
     
     
     
279. 
     Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
     Mult Scler. 2022 Nov 30:13524585221138507. doi: 10.1177/13524585221138507.
     PubMed    
     
     
     
280. BARRO C, Healy BC, Saxena S, Glanz BI, et al
     Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients.
     Mult Scler. 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697.
     PubMed     Abstract available
     
     
     
281. REDER AT, Stuve O, Tankou SK, Leist TP, et al
     T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
     Mult Scler. 2022 Nov 28:13524585221134216. doi: 10.1177/13524585221134216.
     PubMed     Abstract available
     
     
     
282. SPELMAN T, Ozakbas S, Alroughani R, Terzi M, et al
     Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
     Mult Scler. 2022 Nov 26:13524585221137502. doi: 10.1177/13524585221137502.
     PubMed     Abstract available
     
     
     
283. BROWNLEE WJ, Tur C, Manole A, Eshaghi A, et al
     HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis.
     Mult Scler. 2022 Nov 18:13524585221130941. doi: 10.1177/13524585221130941.
     PubMed     Abstract available
     
     
     
284. FOLEY J, Xiong K, Hoyt T, Singh CM, et al
     Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice.
     Mult Scler. 2022 Nov 15:13524585221130949. doi: 10.1177/13524585221130949.
     PubMed     Abstract available
     
     
     
285. VUKUSIC S, Marignier R, Ciron J, Bourre B, et al
     Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
     Mult Scler. 2022 Nov 8:13524585221130934. doi: 10.1177/13524585221130934.
     PubMed     Abstract available
     
     
     
286. BROWNLEE WJ
     Cladribine-induced liver injury: Implications for practice.
     Mult Scler. 2022;28:2146.
     PubMed    
     
     
     
287. CAMARA-LEMARROY C, Metz L, Kuhle J, Leppert D, et al
     Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
     Mult Scler. 2022;28:2081-2089.
     PubMed     Abstract available
     
     
     
288. KIM JE, Park J, Song TJ
     A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database.
     Mult Scler. 2022;28:2112-2123.
     PubMed     Abstract available
     
     
     
289. CACCIAGUERRA L, Mistri D, Valsasina P, Martinelli V, et al
     Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study.
     Mult Scler. 2022;28:2057-2069.
     PubMed     Abstract available
     
     
     
290. VUKUSIC S, Carra-Dalliere C, Ciron J, Maillart E, et al
     Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
     Mult Scler. 2022 Nov 1:13524585221129472. doi: 10.1177/13524585221129472.
     PubMed     Abstract available
     
     
     October 2022
291. CHERTCOFF A, Ng HS, Zhu F, Zhao Y, et al
     Polypharmacy and multiple sclerosis: A population-based study.
     Mult Scler. 2022 Oct 27:13524585221122207. doi: 10.1177/13524585221122207.
     PubMed     Abstract available
     
     
     
292. CALOCER F, Ng HS, Zhu F, Zhao Y, et al
     Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis.
     Mult Scler. 2022 Oct 25:13524585221129963. doi: 10.1177/13524585221129963.
     PubMed     Abstract available
     
     
     
293. DOST-KOVALSKY K, Thiel S, Ciplea AI, Gold R, et al
     Cladribine and pregnancy in women with multiple sclerosis: The first cohort study.
     Mult Scler. 2022 Oct 22:13524585221131486. doi: 10.1177/13524585221131486.
     PubMed     Abstract available
     
     
     
294. CARDENAS-ROBLEDO S, Gonzalez-Caicedo P, Carvajal-Parra MS, Guio-Sanchez CM, et al
     No seasonality in the risk of multiple sclerosis in an equatorial country: A case-control ecological study.
     Mult Scler. 2022 Oct 15:13524585221130020. doi: 10.1177/13524585221130020.
     PubMed     Abstract available
     
     
     
295. BOURDETTE D, Herink M
     Polypharmacy in multiple sclerosis: More is not necessarily better.
     Mult Scler. 2022 Oct 14:13524585221129964. doi: 10.1177/13524585221129964.
     PubMed    
     
     
     
296. HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
     A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS).
     Mult Scler. 2022 Oct 14:13524585221127941. doi: 10.1177/13524585221127941.
     PubMed     Abstract available
     
     
     
297. KATZ SAND I, Levy S, Fitzgerald K, Sorets T, et al
     Mediterranean diet is linked to less objective disability in multiple sclerosis.
     Mult Scler. 2022 Oct 13:13524585221127414. doi: 10.1177/13524585221127414.
     PubMed     Abstract available
     
     
     
298. HUISKAMP M, Kiljan S, Kulik S, Witte ME, et al
     Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study.
     Mult Scler. 2022 Oct 3:13524585221125381. doi: 10.1177/13524585221125381.
     PubMed     Abstract available
     
     
     
299. PAUWELS A, Van Schependom J, Devolder L, Van Remoortel A, et al
     Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
     Mult Scler. 2022;28:1685-1696.
     PubMed     Abstract available
     
     
     
300. FORD CC, Cohen JA, Goodman AD, Lindsey JW, et al
     Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
     Mult Scler. 2022;28:1729-1743.
     PubMed     Abstract available
     
     
     
301. HARDY TA, Guo Y, Flanagan EP, Lucchinetti CF, et al
     The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.
     Mult Scler. 2022;28:1710-1718.
     PubMed     Abstract available
     
     
     
302. CAPANNA M, Signori A, Sormani MP
     Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.
     Mult Scler. 2022;28:1744-1751.
     PubMed     Abstract available
     
     
     
303. ZARGHAMI A, van der Mei I, Hussain MA, Claflin SB, et al
     Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination.
     Mult Scler. 2022;28:1793-1807.
     PubMed     Abstract available
     
     
     
304. GRAF J, Ng HS, Zhu F, Zhao Y, et al
     Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.
     Mult Scler. 2022;28:1825-1828.
     PubMed     Abstract available
     
     
     
305. SALAMA S, Levy M
     Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder.
     Mult Scler. 2022;28:1663-1666.
     PubMed     Abstract available
     
     
     
306. GAETANI L, Schoonheim MM
     Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
     Mult Scler. 2022;28:1831-1833.
     PubMed    
     
     
     
307. KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
     Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
     Mult Scler. 2022;28:1973-1982.
     PubMed     Abstract available
     
     
     
308. ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
     Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
     Mult Scler. 2022;28:1927-1936.
     PubMed     Abstract available
     
     
     
309. BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
     Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
     Mult Scler. 2022;28:1983-1996.
     PubMed     Abstract available
     
     
     
310. 
     ECTRIMS 2022 Committees.
     Mult Scler. 2022;28.
     PubMed    
     
     
     September 2022
311. BUHLER A, Wolbers M, Model F, Wang Q, et al
     Recurrent disability progression endpoints in multiple sclerosis clinical trials.
     Mult Scler. 2022 Sep 30:13524585221125382. doi: 10.1177/13524585221125382.
     PubMed     Abstract available
     
     
     
312. ALEXANDER S, Braisher M, Tur C, Chataway J, et al
     The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis.
     Mult Scler. 2022 Sep 30:13524585221124043. doi: 10.1177/13524585221124043.
     PubMed     Abstract available
     
     
     
313. STRIK M, Eijlers AJ, Dekker I, Broeders TA, et al
     Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis.
     Mult Scler. 2022 Sep 30:13524585221125372. doi: 10.1177/13524585221125372.
     PubMed     Abstract available
     
     
     
314. SARACENO L, Pirro F, Stigliano R, Agostoni EC, et al
     Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders.
     Mult Scler. 2022 Sep 28:13524585221125360. doi: 10.1177/13524585221125360.
     PubMed     Abstract available
     
     
     
315. BRUIJSTENS AL, Stingl C, Guzel C, Stoop MP, et al
     Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood.
     Mult Scler. 2022 Sep 24:13524585221125369. doi: 10.1177/13524585221125369.
     PubMed     Abstract available
     
     
     
316. POL-PATIL J, Glanz B, Safar L, Misasi E, et al
     MeTooMS: Sexual, physical, and emotional abuse experience among women with multiple sclerosis.
     Mult Scler. 2022 Sep 24:13524585221122169. doi: 10.1177/13524585221122169.
     PubMed     Abstract available
     
     
     
317. CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
     Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
     Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
     PubMed     Abstract available
     
     
     
318. COHEN JA, Lublin FD, Lock C, Pelletier D, et al
     Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
     Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
     PubMed     Abstract available
     
     
     
319. VAN LIEROP ZY, Noteboom S, Steenwijk MD, van Dam M, et al
     Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
     Mult Scler. 2022 Sep 3:13524585221118676. doi: 10.1177/13524585221118676.
     PubMed     Abstract available
     
     
     
320. MCGINLEY MP, Lapin B
     The value of patient-reported outcome measures for multiple sclerosis.
     Mult Scler. 2022;28:1489-1490.
     PubMed    
     
     
     
321. MARIGNIER R
     It is imperative to reconsider the concept of seronegative NMOSD.
     Mult Scler. 2022;28:1654-1655.
     PubMed    
     
     
     
322. ROGAWSKI DS, Nirschl JJ, McDonald J, Nie E, et al
     A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma.
     Mult Scler. 2022;28:1651-1654.
     PubMed     Abstract available
     
     
     
323. STRIJBIS EM, Repovic P, Mostert J, Bowen JD, et al
     The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
     Mult Scler. 2022;28:1606-1619.
     PubMed     Abstract available
     
     
     
324. KLISTORNER S, Barnett MH, Graham SL, Wang C, et al
     The expansion and severity of chronic MS lesions follows a periventricular gradient.
     Mult Scler. 2022;28:1504-1514.
     PubMed     Abstract available
     
     
     
325. XIANG B, Brier MR, Kanthamneni M, Wen J, et al
     Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
     Mult Scler. 2022;28:1515-1525.
     PubMed     Abstract available
     
     
     
326. THEBAULT S, Bose G, Booth R, Freedman MS, et al
     Serum neurofilament light in MS: The first true blood-based biomarker?
     Mult Scler. 2022;28:1491-1497.
     PubMed     Abstract available
     
     
     
327. PORTACCIO E, Amato MP
     Reliable change indices for cognitive assessment of patients with multiple sclerosis.
     Mult Scler. 2022 Sep 1:13524585221116273. doi: 10.1177/13524585221116273.
     PubMed    
     
     
     August 2022
328. MEATON I, Altokhis A, Allen CM, Clarke MA, et al
     Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
     Mult Scler. 2022 Aug 26:13524585221118677. doi: 10.1177/13524585221118677.
     PubMed     Abstract available
     
     
     
329. BROWNLEE WJ, Wolf C, Hartung HP, Dingermann T, et al
     Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
     Mult Scler. 2022 Aug 24:13524585221116269. doi: 10.1177/13524585221116269.
     PubMed     Abstract available
     
     
     
330. ALTOKHIS AI, Hibbert AM, Allen CM, Mougin O, et al
     Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis.
     Mult Scler. 2022 Aug 24:13524585221114750. doi: 10.1177/13524585221114750.
     PubMed     Abstract available
     
     
     
331. YOUNG CA, Mills RJ, Langdon D, Rog DJ, et al
     Measuring coping in multiple sclerosis: The Coping Index-MS.
     Mult Scler. 2022 Aug 24:13524585221114004. doi: 10.1177/13524585221114004.
     PubMed     Abstract available
     
     
     
332. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
     Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
     Mult Scler. 2022 Aug 15:13524585221114007. doi: 10.1177/13524585221114007.
     PubMed     Abstract available
     
     
     
333. BLYAU S, Koubiyr I, Saranathan M, Coupe P, et al
     Differential vulnerability of thalamic nuclei in multiple sclerosis.
     Mult Scler. 2022 Aug 12:13524585221114247. doi: 10.1177/13524585221114247.
     PubMed     Abstract available
     
     
     
334. CONWAY SE, Pua DKA, Holroyd KB, Galetta K, et al
     Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.
     Mult Scler. 2022 Aug 11:13524585221117949. doi: 10.1177/13524585221117949.
     PubMed     Abstract available
     
     
     
335. WILLIAMS T, Tur C, Eshaghi A, Doshi A, et al
     Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.
     Mult Scler. 2022 Aug 9:13524585221114441. doi: 10.1177/13524585221114441.
     PubMed     Abstract available
     
     
     
336. CIFTCI KAVAKLIOGLU B, Erdman L, Goldenberg A, Kavaklioglu C, et al
     Machine learning classification of multiple sclerosis in children using optical coherence tomography.
     Mult Scler. 2022 Aug 9:13524585221112605. doi: 10.1177/13524585221112605.
     PubMed     Abstract available
     
     
     
337. UCCELLI A, Freedman MS
     Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No.
     Mult Scler. 2022;28:1326-1328.
     PubMed    
     
     
     
338. PERUZZOTTI-JAMETTI L, Pluchino S
     Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary.
     Mult Scler. 2022;28:1328-1329.
     PubMed    
     
     
     
339. KARUSSIS D, Kassis I, Petrou P
     Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.
     Mult Scler. 2022;28:1324-1326.
     PubMed    
     
     
     
340. GIBBONS E, Whittam D, Elhadd K, Bhojak M, et al
     Progressive myelin oligodendrocyte glycoprotein-associated demyelination mimicking leukodystrophy.
     Mult Scler. 2022;28:1481-1484.
     PubMed     Abstract available
     
     
     
341. ROSTASY K
     A rare but distinct and unique phenotype of MOGAD.
     Mult Scler. 2022;28:1485.
     PubMed    
     
     
     
342. SESEL AL, Sharpe L, Beadnall HN, Barnett MH, et al
     A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression.
     Mult Scler. 2022;28:1392-1401.
     PubMed     Abstract available
     
     
     July 2022
343. TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
     Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
     Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
     PubMed     Abstract available
     
     
     
344. ZHONG M, van der Walt A, Monif M, Hodgkinson S, et al
     Prediction of relapse activity when switching to cladribine for multiple sclerosis.
     Mult Scler. 2022 Jul 27:13524585221111677. doi: 10.1177/13524585221111677.
     PubMed     Abstract available
     
     
     
345. KLISTORNER S, Barnett MH, Klistorner A
     Mechanisms of central brain atrophy in multiple sclerosis.
     Mult Scler. 2022 Jul 21:13524585221111684. doi: 10.1177/13524585221111684.
     PubMed     Abstract available
     
     
     
346. JOHNSSON M, Farman HH, Blennow K, Zetterberg H, et al
     No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
     Mult Scler. 2022 Jul 20:13524585221108080. doi: 10.1177/13524585221108080.
     PubMed     Abstract available
     
     
     
347. MAGYARI M, Joensen H, Kopp TI, Pontieri L, et al
     Changes in prognosis of the Danish multiple sclerosis population over time.
     Mult Scler. 2022 Jul 13:13524585221110582. doi: 10.1177/13524585221110582.
     PubMed     Abstract available
     
     
     
348. KRIEGER SC, Antoine A, Sumowski JF
     EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold.
     Mult Scler. 2022 Jul 13:13524585221108297. doi: 10.1177/13524585221108297.
     PubMed     Abstract available
     
     
     
349. ANNA KARIN H, Erik S, Tim S, Lars F, et al
     The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study.
     Mult Scler. 2022 Jul 7:13524585221107095. doi: 10.1177/13524585221107095.
     PubMed     Abstract available
     
     
     
350. LADAKIS DC, Yao PJ, Vreones M, Blommer J, et al
     Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis.
     Mult Scler. 2022 Jul 5:13524585221106290. doi: 10.1177/13524585221106290.
     PubMed     Abstract available
     
     
     
351. MANUEL ESCOBAR J, Cortese M, Edan G, Freedman MS, et al
     Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
     Mult Scler. 2022;28:1277-1285.
     PubMed     Abstract available
     
     
     
352. W KOCH M, Mostert J, Repovic P, Bowen JD, et al
     Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
     Mult Scler. 2022;28:1286-1298.
     PubMed     Abstract available
     
     
     
353. ANDERSEN JB, Wandall-Holm MF, Andersen PK, Sellebjerg F, et al
     Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort.
     Mult Scler. 2022;28:1239-1247.
     PubMed     Abstract available
     
     
     
354. GIOVANNONI G, Singer BA, Issard D, Jack D, et al
     Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
     Mult Scler. 2022;28:1219-1228.
     PubMed     Abstract available
     
     
     
355. EISELE P, Wittayer M, Weber CE, Platten M, et al
     Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
     Mult Scler. 2022 Jul 1:13524585221106338. doi: 10.1177/13524585221106338.
     PubMed     Abstract available
     
     
     June 2022
356. PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
     A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
     Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
     PubMed     Abstract available
     
     
     
357. CREE BA, Selmaj KW, Steinman L, Comi G, et al
     Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
     Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
     PubMed     Abstract available
     
     
     
358. MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
     Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
     Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
     PubMed     Abstract available
     
     
     
359. MAGNE F, Cellerino M, Balletto E, Aluan K, et al
     Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
     Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
     PubMed    
     
     
     
360. HEMOND CC, Baek J, Ionete C, Reich DS, et al
     Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study.
     Mult Scler. 2022 Jun 24:13524585221102921. doi: 10.1177/13524585221102921.
     PubMed     Abstract available
     
     
     
361. SCHIAVETTI I, Cordioli C, Stromillo ML, Teresa Ferro M, et al
     Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
     Mult Scler. 2022 Jun 23:13524585221102918. doi: 10.1177/13524585221102918.
     PubMed     Abstract available
     
     
     
362. GARJANI A, Liu BJ, Allen CM, Gunzler DD, et al
     Decentralised clinical trials in multiple sclerosis research.
     Mult Scler. 2022 Jun 23:13524585221100401. doi: 10.1177/13524585221100401.
     PubMed     Abstract available
     
     
     
363. MAAROUF A, Audoin B, Gherib S, El Mendili MM, et al
     Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
     Mult Scler. 2022 Jun 20:13524585221102587. doi: 10.1177/13524585221102587.
     PubMed     Abstract available
     
     
     
364. GUERRERA G, Mandelli A, Finardi A, Orrico M, et al
     Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
     Mult Scler. 2022 Jun 20:13524585221102158. doi: 10.1177/13524585221102158.
     PubMed     Abstract available
     
     
     
365. LAZZAROTTO A, Tonietto M, Poirion E, Battaglini M, et al
     Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartment imaging study.
     Mult Scler. 2022 Jun 16:13524585221096975. doi: 10.1177/13524585221096975.
     PubMed     Abstract available
     
     
     
366. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
     Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
     Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
     PubMed     Abstract available
     
     
     
367. AL-LOUZI O, Manukyan S, Donadieu M, Absinta M, et al
     Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.
     Mult Scler. 2022 Jun 8:13524585221097560. doi: 10.1177/13524585221097560.
     PubMed     Abstract available
     
     
     
368. SCHMIERER K, Wiendl H, Oreja-Guevara C, Centonze D, et al
     Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
     Mult Scler. 2022 Jun 7:13524585221099413. doi: 10.1177/13524585221099413.
     PubMed    
     
     
     
369. BRUNE S, Hogestol EA, de Rodez Benavent SA, Berg-Hansen P, et al
     Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.
     Mult Scler. 2022 Jun 4:13524585221097296. doi: 10.1177/13524585221097296.
     PubMed     Abstract available
     
     
     
370. LEAVITT VM, Dworkin JD, Buyukturkoglu K, Riley CS, et al
     Summary metrics of memory subnetwork functional connectivity alterations in multiple sclerosis.
     Mult Scler. 2022 Jun 4:13524585221099169. doi: 10.1177/13524585221099169.
     PubMed     Abstract available
     
     
     
371. BEREK K, Hegen H, Hocher J, Auer M, et al
     Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
     Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
     PubMed     Abstract available
     
     
     
372. CARCAMO C, Ciampi E
     Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
     Mult Scler. 2022;28:1032-1033.
     PubMed    
     
     
     
373. PIEHL F, Mathew T
     Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
     Mult Scler. 2022;28:1028-1029.
     PubMed    
     
     
     
374. MATEEN FJ
     Low-dose rituximab should be used for treating MS in resource-limited settings: No.
     Mult Scler. 2022;28:1030-1032.
     PubMed    
     
     
     
375. WRIGHT S
     MOG antibody-associated longitudinal extensive myelitis after Oxford-Astra Zeneca's COVID-19 vaccination.
     Mult Scler. 2022;28:1163.
     PubMed    
     
     
     
376. DAMS L, Kraemer M, Becker J
     MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination.
     Mult Scler. 2022;28:1159-1162.
     PubMed     Abstract available
     
     
     
377. RINALDI V, Bellucci G, Romano A, Bozzao A, et al
     ADEM after ChAdOx1 nCoV-19 vaccine: A case report.
     Mult Scler. 2022;28:1151-1154.
     PubMed     Abstract available
     
     
     
378. PODDA J, Tacchino A, Pedulla L, Monti Bragadin M, et al
     Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
     Mult Scler. 2022;28:1009-1019.
     PubMed     Abstract available
     
     
     May 2022
379. COFRE LIZAMA LE, Strik M, Van der Walt A, Kilpatrick TJ, et al
     Gait stability reflects motor tracts damage at early stages of multiple sclerosis.
     Mult Scler. 2022 May 21:13524585221094464. doi: 10.1177/13524585221094464.
     PubMed     Abstract available
     
     
     
380. FADDA G, Waters P, Woodhall M, Brown RA, et al
     Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
     Mult Scler. 2022 May 17:13524585221093789. doi: 10.1177/13524585221093789.
     PubMed     Abstract available
     
     
     
381. GONZALEZ-MARTINEZ A, Bose G, Chitnis T
     Anti-CGRP therapies for migraine in multiple sclerosis patients.
     Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353.
     PubMed    
     
     
     
382. SCHWARZ T, Otto C, Jones TC, Pache F, et al
     Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
     Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478.
     PubMed     Abstract available
     
     
     
383. LEUNG MW, Bazelier MT, Souverein PC, Uitdehaag BM, et al
     Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
     Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218.
     PubMed     Abstract available
     
     
     
384. ALMRAMHI MM, Storm CS, Kia DA, Coneys R, et al
     The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study.
     Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644.
     PubMed     Abstract available
     
     
     
385. CHIARAVALLOTI ND, DeLuca J, Salter A, Amato MP, et al
     The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
     Mult Scler. 2022 May 9:13524585221088190. doi: 10.1177/13524585221088190.
     PubMed     Abstract available
     
     
     
386. MANGLANI HR, Fisher ME, Duraney EJ, Nicholas JA, et al
     A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures.
     Mult Scler. 2022 May 9:13524585221088731. doi: 10.1177/13524585221088731.
     PubMed     Abstract available
     
     
     
387. HYUN JW, Lee HL, Park J, Kim J, et al
     Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
     Mult Scler. 2022;28:989-992.
     PubMed     Abstract available
     
     
     
388. VALSASINA P, Gobbi C, Zecca C, Rovira A, et al
     Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.
     Mult Scler. 2022;28:885-899.
     PubMed     Abstract available
     
     
     
389. RENSEL M, Zabeti A, Mealy MA, Cimbora D, et al
     Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for 4 years in the N-MOmentum trial.
     Mult Scler. 2022;28:925-932.
     PubMed     Abstract available
     
     
     
390. ROSENSTEIN I, Axelsson M, Novakova L, Blennow K, et al
     Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
     Mult Scler. 2022;28:872-884.
     PubMed     Abstract available
     
     
     
391. 
     ACTRIMS Forum 2022.
     Mult Scler. 2022;28.
     PubMed    
     
     
     April 2022
392. SPRENGER T, Kappos L, Sormani MP, Miller AE, et al
     Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
     Mult Scler. 2022 Apr 29:13524585221089534. doi: 10.1177/13524585221089534.
     PubMed     Abstract available
     
     
     
393. DEGRAEVE B, Sequeira H, Mecheri H, Lenne B, et al
     Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?
     Mult Scler. 2022 Apr 27:13524585221091067. doi: 10.1177/13524585221091067.
     PubMed     Abstract available
     
     
     
394. MANZANO GS, Rice DR, Klawiter EC, Matiello M, et al
     Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
     Mult Scler. 2022 Apr 27:13524585221092309. doi: 10.1177/13524585221092309.
     PubMed     Abstract available
     
     
     
395. ZABALZA A, Arrambide G, Otero-Romero S, Pappolla A, et al
     Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
     Mult Scler. 2022 Apr 27:13524585221089540. doi: 10.1177/13524585221089540.
     PubMed     Abstract available
     
     
     
396. SIMONEAU G, Pellegrini F, Debray TP, Rouette J, et al
     Recommendations for the use of propensity score methods in multiple sclerosis research.
     Mult Scler. 2022 Apr 6:13524585221085733. doi: 10.1177/13524585221085733.
     PubMed     Abstract available
     
     
     
397. CREE BA, Arnold DL, Fox RJ, Gold R, et al
     Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
     Mult Scler. 2022 Apr 5:13524585221083194. doi: 10.1177/13524585221083194.
     PubMed     Abstract available
     
     
     
398. KALINCIK T, Kister I, Bacon TE, Malpas CB, et al
     Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
     Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577.
     PubMed     Abstract available
     
     
     
399. MOCCIA M, Affinito G, Ronga B, Giordana R, et al
     Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).
     Mult Scler. 2022;28:597-607.
     PubMed     Abstract available
     
     
     
400. GRATCH D, Zhovtis Ryerson L
     Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
     Mult Scler. 2022;28:695-696.
     PubMed    
     
     
     
401. INES CIPLEA A, Kurzeja A, Thiel S, Haben S, et al
     Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
     Mult Scler. 2022 Apr 1:13524585221083982. doi: 10.1177/13524585221083982.
     PubMed     Abstract available
     
     
     
402. TZANETAKOS D, Tzartos JS, Vakrakou AG, Breza M, et al
     Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study.
     Mult Scler. 2022;28:718-729.
     PubMed     Abstract available
     
     
     
403. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
     Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.
     Mult Scler. 2022;28:697-706.
     PubMed     Abstract available
     
     
     
404. ALY L, Strauss EM, Feucht N, Weiss I, et al
     Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.
     Mult Scler. 2022;28:522-531.
     PubMed     Abstract available
     
     
     
405. ABDEL-MANNAN O, Klein A, Bachar Zipori A, Ben-Sira L, et al
     Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.
     Mult Scler. 2022;28:676-679.
     PubMed     Abstract available
     
     
     
406. ROTSTEIN DL
     Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD.
     Mult Scler. 2022;28:679-680.
     PubMed    
     
     
     
407. KIM KH, Kim SH, Park NY, Hyun JW, et al
     Reappraisal of CSF-specific oligoclonal bands in Asia.
     Mult Scler. 2022;28:665-668.
     PubMed     Abstract available
     
     
     
408. KUHLE J, Daizadeh N, Benkert P, Maceski A, et al
     Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
     Mult Scler. 2022;28:573-582.
     PubMed     Abstract available
     
     
     
409. BAJRAMI A, Magliozzi R, Pisani AI, Pizzini FB, et al
     Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS.
     Mult Scler. 2022;28:550-560.
     PubMed     Abstract available
     
     
     
410. KIM H, Lee EJ, Kim S, Choi LK, et al
     Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder.
     Mult Scler. 2022;28:512-521.
     PubMed     Abstract available
     
     
     
411. VALENTINE TR, Alschuler KN, Ehde DM, Kratz AL, et al
     Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.
     Mult Scler. 2022;28:620-631.
     PubMed     Abstract available
     
     
     March 2022
412. GASPERI C, Hapfelmeier A, Schneider A, Kuhn KA, et al
     Association of pregnancies with risk of multiple sclerosis.
     Mult Scler. 2022 Mar 18:13524585221080542. doi: 10.1177/13524585221080542.
     PubMed     Abstract available
     
     
     
413. PORTACCIO E, Pasto L, Razzolini L, Moiola L, et al
     Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
     Mult Scler. 2022 Mar 16:13524585221079598. doi: 10.1177/13524585221079598.
     PubMed     Abstract available
     
     
     
414. RIEMENSCHNEIDER M, Hvid LG, Ringgaard S, Nygaard MKE, et al
     Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
     Mult Scler. 2022 Mar 16:13524585221079200. doi: 10.1177/13524585221079200.
     PubMed     Abstract available
     
     
     
415. CARLSON A, McGinley MP
     Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.
     Mult Scler. 2022 Mar 16:13524585221081985. doi: 10.1177/13524585221081985.
     PubMed    
     
     
     
416. LIANG G, Zhu F, Mirza AI, Bar-Or A, et al
     Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases.
     Mult Scler. 2022 Mar 16:13524585221079533. doi: 10.1177/13524585221079533.
     PubMed     Abstract available
     
     
     
417. JACOBS BM, Watson C, Marshall C, Noyce A, et al
     No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
     Mult Scler. 2022 Mar 16:13524585221075744. doi: 10.1177/13524585221075744.
     PubMed    
     
     
     
418. DALGAS U, Stenager E, Hvid LG
     Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary.
     Mult Scler. 2022 Mar 16:13524585211072702. doi: 10.1177/13524585211072702.
     PubMed    
     
     
     
419. MOTL RW, Sandroff BM
     Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect-Yes.
     Mult Scler. 2022 Mar 16:13524585211061651. doi: 10.1177/13524585211061651.
     PubMed    
     
     
     
420. HEESEN C, Rosenkranz SC
     Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
     Mult Scler. 2022 Mar 16:13524585211064968. doi: 10.1177/13524585211064968.
     PubMed    
     
     
     
421. WENDEL EM, Bertolini A, Kousoulos L, Rauchenzauner M, et al
     Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
     Mult Scler. 2022 Mar 14:13524585221081090. doi: 10.1177/13524585221081090.
     PubMed     Abstract available
     
     
     
422. BSTEH G, Hegen H, Berek K, Altmann P, et al
     Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
     Mult Scler. 2022 Mar 12:13524585221079744. doi: 10.1177/13524585221079744.
     PubMed     Abstract available
     
     
     
423. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
     Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
     Mult Scler. 2022 Mar 12:13524585221079044. doi: 10.1177/13524585221079044.
     PubMed    
     
     
     
424. GARTNER J, Hauser SL, Bar-Or A, Montalban X, et al
     Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
     Mult Scler. 2022 Mar 10:13524585221078825. doi: 10.1177/13524585221078825.
     PubMed     Abstract available
     
     
     
425. ARNOLD DL, Piani-Meier D, Bar-Or A, Benedict RH, et al
     Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
     Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717.
     PubMed     Abstract available
     
     
     
426. BEBO BF JR, Allegretta M, Landsman D, Zackowski KM, et al
     Pathways to cures for multiple sclerosis: A research roadmap.
     Mult Scler. 2022;28:331-345.
     PubMed     Abstract available
     
     
     
427. HAUSER SL, Cross AH, Winthrop K, Wiendl H, et al
     Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
     Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
     PubMed     Abstract available
     
     
     
428. PITTOCK SJ, Fujihara K, Palace J, Berthele A, et al
     Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
     Mult Scler. 2022;28:480-486.
     PubMed     Abstract available
     
     
     
429. PORTACCIO E, Tudisco L, Pasto L, Razzolini L, et al
     Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
     Mult Scler. 2022;28:472-479.
     PubMed     Abstract available
     
     
     
430. VAVASOUR IM, Sun P, Graf C, Yik JT, et al
     Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
     Mult Scler. 2022;28:418-428.
     PubMed     Abstract available
     
     
     February 2022
431. TUR C, Dubessy AL, Otero-Romero S, Amato MP, et al
     The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
     Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068.
     PubMed     Abstract available
     
     
     
432. SHAFIN N, Ismail CAN, Mustafa MZ, Ghani N, et al
     Thematic analysis of multiple sclerosis research by enhanced strategic diagram.
     Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542.
     PubMed     Abstract available
     
     
     
433. 
     Erratum to "Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward".
     Mult Scler. 2022 Feb 11:13524585221079450. doi: 10.1177/13524585221079450.
     PubMed    
     
     
     
434. BECK ES, Maranzano J, Luciano NJ, Parvathaneni P, et al
     Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.
     Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167.
     PubMed     Abstract available
     
     
     
435. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Patten S, et al
     Productivity loss among people with early multiple sclerosis: A Canadian study.
     Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070.
     PubMed     Abstract available
     
     
     
436. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
     The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents.
     Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521.
     PubMed     Abstract available
     
     
     
437. HOLM HANSEN R, Hojsgaard Chow H, Talbot J, Buhelt S, et al
     Peripheral helper T cells in the pathogenesis of multiple sclerosis.
     Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696.
     PubMed     Abstract available
     
     
     
438. DOBSON R, Chung K
     Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
     Mult Scler. 2022;28:326-327.
     PubMed    
     
     
     
439. COYLE PK, Syritsyna O
     DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
     Mult Scler. 2022;28:183-185.
     PubMed    
     
     
     
440. BERMEL RA
     DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - No.
     Mult Scler. 2022;28:185-187.
     PubMed    
     
     
     
441. FOX RJ, Tintore M
     DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.
     Mult Scler. 2022;28:187-188.
     PubMed    
     
     
     
442. HILLERT J, Tsai JA, Nouhi M, Glaser A, et al
     A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
     Mult Scler. 2022;28:237-246.
     PubMed     Abstract available
     
     
     
443. ZHENG Y, Dudman J, Chen JT, Mahajan KR, et al
     Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
     Mult Scler. 2022;28:198-205.
     PubMed     Abstract available
     
     
     
444. PFEUFFER S, Rolfes L, Hackert J, Kleinschnitz K, et al
     Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
     Mult Scler. 2022;28:257-268.
     PubMed     Abstract available
     
     
     January 2022
445. LIAO CM, Kuo WY, Kung PT, Chuan CH, et al
     Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan.
     Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341.
     PubMed     Abstract available
     
     
     
446. NAKAMURA K, Zheng Y, Ontaneda D
     T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes.
     Mult Scler. 2022 Jan 22:13524585211066313. doi: 10.1177/13524585211066313.
     PubMed    
     
     
     
447. MUHLAU M
     T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.
     Mult Scler. 2022 Jan 22:13524585211063622. doi: 10.1177/13524585211063622.
     PubMed    
     
     
     
448. ROVIRA A, Pareto D
     T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary.
     Mult Scler. 2022 Jan 22:13524585211069363. doi: 10.1177/13524585211069363.
     PubMed    
     
     
     
449. KEVER A, Riley CS, Leavitt VM
     Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis.
     Mult Scler. 2022 Jan 16:13524585211070496. doi: 10.1177/13524585211070496.
     PubMed     Abstract available
     
     
     
450. P MOSS B, Miller DM
     Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward.
     Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668.
     PubMed    
     
     
     
451. BELVISI D, Canevelli M, Marfia GA, Ferraro E, et al
     Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework".
     Mult Scler. 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150.
     PubMed    
     
     
     
452. ZIAEI A, Lavery AM, Shao XM, Adams C, et al
     Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.
     Mult Scler. 2022 Jan 8:13524585211069926. doi: 10.1177/13524585211069926.
     PubMed     Abstract available
     
     
     
453. VAN KEMPEN ZL, Hogenboom L, Killestein J
     Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
     Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441.
     PubMed    
     
     
     
454. COHEN JA, Bermel RA, Grossman CI, Hersh CM, et al
     Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
     Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343.
     PubMed     Abstract available
     
     
     
455. THOMPSON AJ, Carroll W, Ciccarelli O, Comi G, et al
     Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
     Mult Scler. 2022;28:16-28.
     PubMed     Abstract available
     
     
     
456. TARDO L, Wang C, Rajaram V, Greenberg BM, et al
     Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma.
     Mult Scler. 2022;28:160-163.
     PubMed     Abstract available
     
     
     
457. ABDEL-MANNAN O, Hacohen Y
     Aquaporin-4 antibody neuromyelitis optica spectrum disorder: A paraneoplastic disease?
     Mult Scler. 2022;28:163-164.
     PubMed    
     
     
     
458. TAJFIROUZ D, Padungkiatsagul T, Beres S, Moss HE, et al
     Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder.
     Mult Scler. 2022;28:149-153.
     PubMed     Abstract available
     
     
     
459. COMABELLA M, Clarke MA, Schaedelin S, Tintore M, et al
     CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
     Mult Scler. 2022;28:71-81.
     PubMed     Abstract available
     
     
     
460. SIGNORIELLO E, Lus G, Bonavita S, Lanzillo R, et al
     Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
     Mult Scler. 2022;28:93-101.
     PubMed     Abstract available
     
     
     December 2021
461. GAITAN MI, Sanchez M, Farez MF, Fiol MP, et al
     The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.
     Mult Scler. 2021 Dec 31:13524585211067521. doi: 10.1177/13524585211067521.
     PubMed     Abstract available
     
     
     
462. BERNARDI G, Biagioli T, Malpassi P, De Michele T, et al
     The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.
     Mult Scler. 2021 Dec 30:13524585211064121. doi: 10.1177/13524585211064121.
     PubMed     Abstract available
     
     
     
463. CAVACO S, Ferreira I, Moreira I, Santos E, et al
     Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.
     Mult Scler. 2021 Dec 30:13524585211066598. doi: 10.1177/13524585211066598.
     PubMed     Abstract available
     
     
     
464. VAN KEMPEN ZL, Toorop AA, Sellebjerg F, Giovannoni G, et al
     Extended dosing of monoclonal antibodies in multiple sclerosis.
     Mult Scler. 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711.
     PubMed     Abstract available
     
     
     
465. NG HS, Zhu F, Kingwell E, Zhao Y, et al
     Disease-modifying drugs for multiple sclerosis and subsequent health service use.
     Mult Scler. 2021 Dec 24:13524585211063403. doi: 10.1177/13524585211063403.
     PubMed     Abstract available
     
     
     
466. FERNANDEZ RS, Crivelli L, Pedreira ME, Allegri RF, et al
     Computational basis of decision-making impairment in multiple sclerosis.
     Mult Scler. 2021 Dec 21:13524585211059308. doi: 10.1177/13524585211059308.
     PubMed     Abstract available
     
     
     
467. ZANOTTO T, Lynch SG, Hausdorff JM, Sosnoff JJ, et al
     Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.
     Mult Scler. 2021 Dec 21:13524585211061332. doi: 10.1177/13524585211061332.
     PubMed    
     
     
     
468. ROLFES L, Meuth SG
     Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
     Mult Scler. 2021 Dec 21:13524585211055593. doi: 10.1177/13524585211055593.
     PubMed    
     
     
     
469. TOOROP AA, Rispens T, Strijbis EM, van Oosten BW, et al
     Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
     Mult Scler. 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168.
     PubMed     Abstract available
     
     
     
470. JANUEL E, De Seze J, Vermersch P, Maillart E, et al
     Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
     Mult Scler. 2021 Dec 21:13524585211049737. doi: 10.1177/13524585211049737.
     PubMed     Abstract available
     
     
     
471. COLES AJ, Jones JL, Vermersch P, Traboulsee A, et al
     Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
     Mult Scler. 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
     PubMed     Abstract available
     
     
     
472. ROVIRA A, Corral JF, Auger C, Valverde S, et al
     Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.
     Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
     PubMed     Abstract available
     
     
     
473. LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
     Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
     Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
     PubMed     Abstract available
     
     
     
474. VAN KEMPEN ZL, Killestein J, Hartung HP
     Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.
     Mult Scler. 2021;27:2123-2125.
     PubMed    
     
     
     
475. NOURBAKHSH B
     Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
     Mult Scler. 2021;27:2290.
     PubMed    
     
     
     
476. LEHMANN H, Zveik O, Levin N, Brill L, et al
     Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses.
     Mult Scler. 2021;27:2232-2239.
     PubMed     Abstract available
     
     
     
477. OH J, Suthiphosuwan S, Sati P, Absinta M, et al
     Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.
     Mult Scler. 2021;27:2199-2208.
     PubMed     Abstract available
     
     
     November 2021
478. SARKAR P, Redondo J, Hares K, Bailey S, et al
     Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
     Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
     PubMed     Abstract available
     
     
     
479. OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
     Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
     Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
     PubMed     Abstract available
     
     
     
480. KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
     Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
     Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
     PubMed     Abstract available
     
     
     
481. SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
     Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
     Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
     PubMed     Abstract available
     
     
     
482. MARRIE RA, McKay K
     Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
     Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.
     PubMed    
     
     
     
483. MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
     Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
     Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
     PubMed     Abstract available
     
     
     
484. MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
     Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
     Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
     PubMed     Abstract available
     
     
     
485. CREE BA, Bennett JL, Kim HJ, Weinshenker BG, et al
     Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
     Mult Scler. 2021;27:2052-2061.
     PubMed     Abstract available
     
     
     
486. DAHLKE F, Arnold DL, Aarden P, Ganjgahi H, et al
     Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
     Mult Scler. 2021;27:2062-2076.
     PubMed     Abstract available
     
     
     October 2021
487. MISICKA E, Davis MF, Kim W, Brugger SW, et al
     A higher burden of multiple sclerosis genetic risk confers an earlier onset.
     Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
     PubMed     Abstract available
     
     
     
488. PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
     Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
     Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
     PubMed     Abstract available
     
     
     
489. BERGAMASCHI R, Montomoli C
     Air pollution is a risk factor for multiple sclerosis - Yes.
     Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
     PubMed    
     
     
     
490. DELGADO-GARCIA G, Corona T
     Air pollution is a risk factor for multiple sclerosis - No.
     Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
     PubMed    
     
     
     
491. SAHRAIAN MA
     Air pollution is a risk factor for multiple sclerosis - Commentary.
     Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
     PubMed    
     
     
     
492. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
     Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
     Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
     PubMed     Abstract available
     
     
     
493. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
     Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
     Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
     PubMed     Abstract available
     
     
     
494. VILLOSLADA P
     Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
     Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
     PubMed    
     
     
     
495. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
     Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
     Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
     PubMed     Abstract available
     
     
     
496. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
     Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
     Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
     PubMed     Abstract available
     
     
     
497. BOSMA AR, Murley C, Aspling J, Hillert J, et al
     Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
     Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
     PubMed     Abstract available
     
     
     
498. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
     Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
     Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
     PubMed     Abstract available
     
     
     
499. GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
     Epilepsy as a predictor of disease progression in multiple sclerosis.
     Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
     PubMed     Abstract available
     
     
     
500. SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
     Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
     Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
     PubMed     Abstract available
     
     
     
501. BSTEH G, Durauer S, Assar H, Hegen H, et al
     Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
     Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
     PubMed     Abstract available
     
     
     
502. GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
     Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
     Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
     PubMed     Abstract available
     
     
     
503. CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
     Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
     Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
     PubMed     Abstract available
     
     
     
504. ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
     Hypertension and hypertension severity in Hispanics/Latinx with MS.
     Mult Scler. 2021;27:1894-1901.
     PubMed     Abstract available
     
     
     
505. ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
     Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
     Mult Scler. 2021;27:1829-1837.
     PubMed     Abstract available
     
     
     
506. KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
     A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
     Mult Scler. 2021;27:1864-1874.
     PubMed     Abstract available
     
     
     
507. KOCH MW, Metz L, Cutter G
     An enrichment strategy for clinical trials in SPMS.
     Mult Scler. 2021;27:1884-1893.
     PubMed     Abstract available
     
     
     
508. MHANNA E, Nouchi A, Louapre C, De Paz R, et al
     Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
     Mult Scler. 2021;27:1794-1798.
     PubMed     Abstract available
     
     
     
509. DE MOL CL, Bruijstens AL, Jansen PR, Dremmen M, et al
     Prevalence of radiologically isolated syndrome in a pediatric population-based cohort: A longitudinal description of a rare diagnosis.
     Mult Scler. 2021;27:1790-1793.
     PubMed     Abstract available
     
     
     
510. CAPUANO R, Zubizarreta I, Alba-Arbalat S, Sepulveda M, et al
     Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability.
     Mult Scler. 2021;27:1706-1716.
     PubMed     Abstract available
     
     
     
511. MACARON G, Khoury J, Bena J, Seay M, et al
     Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder.
     Mult Scler. 2021;27:1749-1759.
     PubMed     Abstract available
     
     
     
512. FILIPPATOU AG, Vasileiou ES, He Y, Fitzgerald KC, et al
     Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD.
     Mult Scler. 2021;27:1738-1748.
     PubMed     Abstract available
     
     
     
513. ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
     Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
     Mult Scler. 2021;27:1643-1656.
     PubMed     Abstract available
     
     
     September 2021
514. BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
     Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
     Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
     PubMed     Abstract available
     
     
     
515. KEVER A, Leavitt VM
     Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
     Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
     PubMed     Abstract available
     
     
     
516. KRYSKO KM, Anderson A, Singh J, McPolin K, et al
     Risk factors for peripartum depression in women with multiple sclerosis.
     Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
     PubMed     Abstract available
     
     
     
517. WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
     Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
     Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
     PubMed     Abstract available
     
     
     
518. TREMLETT H, Okuda DT, Lebrun-Frenay C
     The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
     Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.
     PubMed    
     
     
     
519. GNANAPAVAN S
     The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
     Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.
     PubMed    
     
     
     
520. MAKHANI N
     The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
     Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.
     PubMed    
     
     
     
521. BRADLEY L
     Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
     Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
     PubMed     Abstract available
     
     
     
522. ENZINGER C
     Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
     Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.
     PubMed    
     
     
     
523. HARTUNG HP, Meuth SG, Thompson AJ
     Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
     Mult Scler. 2021;27:1473-1476.
     PubMed    
     
     
     
524. GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
     Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
     Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
     PubMed     Abstract available
     
     
     
525. IAFFALDANO P, Lucisano G, Butzkueven H, Hillert J, et al
     Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network.
     Mult Scler. 2021;27:1543-1555.
     PubMed     Abstract available
     
     
     
526. DALLA COSTA G, Croese T, Pisa M, Finardi A, et al
     CSF extracellular vesicles and risk of disease activity after a first demyelinating event.
     Mult Scler. 2021;27:1606-1610.
     PubMed     Abstract available
     
     
     
527. SCHNEIDER-HOHENDORF T, Schulte-Mecklenbeck A, Ostkamp P, Janoschka C, et al
     High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
     Mult Scler. 2021;27:1491-1496.
     PubMed     Abstract available
     
     
     
528. COHEN M, Mondot L, Bucciarelli F, Pignolet B, et al
     BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
     Mult Scler. 2021;27:1556-1563.
     PubMed     Abstract available
     
     
     
529. THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
     Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
     Mult Scler. 2021;27:1477-1485.
     PubMed     Abstract available
     
     
     August 2021
530. CONWAY DS, Marck CH
     Comorbidities require special attention in minorities with multiple sclerosis.
     Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
     PubMed    
     
     
     
531. BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
     Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
     Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
     PubMed     Abstract available
     
     
     
532. COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
     A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
     Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
     PubMed     Abstract available
     
     
     
533. GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
     Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
     Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
     PubMed     Abstract available
     
     
     
534. ALONSO R, Galleguillos L
     Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
     Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
     PubMed    
     
     
     
535. ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
     Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
     Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
     PubMed     Abstract available
     
     
     
536. BUTLER PAGNOTTI R, Hua LH, Miller JB
     Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
     Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
     PubMed     Abstract available
     
     
     
537. TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
     Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
     Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
     PubMed     Abstract available
     
     
     
538. ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
     SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
     Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.
     PubMed    
     
     
     
539. MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
     Functional and structural MRI correlates of executive functions in multiple sclerosis.
     Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
     PubMed     Abstract available
     
     
     
540. CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
     The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
     Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
     PubMed     Abstract available
     
     
     
541. WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
     Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
     Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
     PubMed     Abstract available
     
     
     
542. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
     White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
     Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
     PubMed     Abstract available
     
     
     
543. AYADI N, Oertel FC, Asseyer S, Rust R, et al
     Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
     Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
     PubMed     Abstract available
     
     
     
544. ZHENG F, Li Y, Zhuo Z, Duan Y, et al
     Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
     Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
     PubMed     Abstract available
     
     
     
545. COMI G, Dadon Y, Sasson N, Steinerman JR, et al
     CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
     Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
     PubMed     Abstract available
     
     
     
546. PANDIT L
     Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
     Mult Scler. 2021;27:1320-1322.
     PubMed    
     
     
     
547. KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
     CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
     Mult Scler. 2021;27:1464-1467.
     PubMed     Abstract available
     
     
     
548. ZHUO Z, Duan Y, Tian D, Wang X, et al
     Brain structural and functional alterations in MOG antibody disease.
     Mult Scler. 2021;27:1350-1363.
     PubMed     Abstract available
     
     
     
549. YAVARPOUR-BALI H, Ghasemi-Kasman M
     The role of inflammasomes in multiple sclerosis.
     Mult Scler. 2021;27:1323-1331.
     PubMed     Abstract available
     
     
     July 2021
550. SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
     SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
     Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
     PubMed     Abstract available
     
     
     
551. ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
     High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
     Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
     PubMed     Abstract available
     
     
     
552. PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
     Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
     Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
     PubMed     Abstract available
     
     
     
553. UHR L, Mateen FJ
     COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
     Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
     PubMed     Abstract available
     
     
     
554. LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
     Ethical use of off-label disease-modifying therapies for multiple sclerosis.
     Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
     PubMed     Abstract available
     
     
     
555. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
     MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
     Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
     PubMed     Abstract available
     
     
     
556. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
     Risk of depression in multiple sclerosis across disease-modifying therapies.
     Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
     PubMed     Abstract available
     
     
     
557. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
     Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
     Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
     PubMed     Abstract available
     
     
     
558. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
     A smartphone sensor-based digital outcome assessment of multiple sclerosis.
     Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
     PubMed     Abstract available
     
     
     
559. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
     Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
     Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
     PubMed     Abstract available
     
     
     
560. WIJERATNE T, Carroll W
     World Brain Day 2021: Global campaign to stop multiple sclerosis.
     Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
     PubMed    
     
     
     
561. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
     Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
     Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
     PubMed     Abstract available
     
     
     
562. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
     Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
     Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
     PubMed     Abstract available
     
     
     
563. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
     Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
     Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
     PubMed     Abstract available
     
     
     
564. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
     Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
     Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
     PubMed     Abstract available
     
     
     
565. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
     Performance validity in outpatients with multiple sclerosis and cognitive complaints.
     Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
     PubMed     Abstract available
     
     
     
566. ESHAGHI A
     Towards an objective classification of multiple sclerosis.
     Mult Scler. 2021;27:1151-1152.
     PubMed    
     
     
     
567. CALDITO NG, O'Leary S, Stuve O
     Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
     Mult Scler. 2021;27:1306-1308.
     PubMed     Abstract available
     
     
     
568. MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
     Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
     Mult Scler. 2021;27:1284-1292.
     PubMed     Abstract available
     
     
     
569. CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
     Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
     Mult Scler. 2021;27:1187-1197.
     PubMed     Abstract available
     
     
     
570. OTALLAH S
     Acute disseminated encephalomyelitis in children and adults: A focused review emphasizing new developments.
     Mult Scler. 2021;27:1153-1160.
     PubMed     Abstract available
     
     
     June 2021
571. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
     Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
     Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
     PubMed     Abstract available
     
     
     
572. MIZELL R, Chen H, Lambe J, Saidha S, et al
     Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
     Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
     PubMed     Abstract available
     
     
     
573. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
     Altered anterior default mode network dynamics in progressive multiple sclerosis.
     Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
     PubMed     Abstract available
     
     
     
574. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
     Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
     Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
     PubMed     Abstract available
     
     
     
575. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
     High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
     Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
     PubMed     Abstract available
     
     
     
576. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
     Acute and chronic synaptic pathology in multiple sclerosis gray matter.
     Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
     PubMed     Abstract available
     
     
     
577. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
     Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
     Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
     PubMed     Abstract available
     
     
     
578. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
     Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
     Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
     PubMed     Abstract available
     
     
     
579. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
     The timed 25-foot walk in a large cohort of multiple sclerosis patients.
     Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
     PubMed     Abstract available
     
     
     
580. GARJANI A, Hunter R, Law GR, Middleton RM, et al
     Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
     Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
     PubMed     Abstract available
     
     
     
581. SCHMIERER K, Giovannoni G
     MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
     Mult Scler. 2021;27:1006-1007.
     PubMed    
     
     
     
582. SCALFARI A
     MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
     Mult Scler. 2021;27:1002-1004.
     PubMed    
     
     
     
583. CROSS AH, Naismith RT
     MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
     Mult Scler. 2021;27:1004-1005.
     PubMed    
     
     
     
584. ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
     Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
     Mult Scler. 2021;27:989-1001.
     PubMed     Abstract available
     
     
     
585. MORROW SA, Conway D, Fuchs T, Wojcik C, et al
     Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
     Mult Scler. 2021;27:1077-1087.
     PubMed     Abstract available
     
     
     
586. NAYAK S, Sechi E, Flanagan EP, Messina S, et al
     Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
     Mult Scler. 2021;27:1037-1045.
     PubMed     Abstract available
     
     
     
587. REDER AT
     Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
     Mult Scler. 2021;27:1008-1013.
     PubMed     Abstract available
     
     
     May 2021
588. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
     Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
     Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
     PubMed     Abstract available
     
     
     
589. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
     Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
     Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
     PubMed     Abstract available
     
     
     
590. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
     Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
     Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
     PubMed     Abstract available
     
     
     
591. MCMURRAN CE
     Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
     Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
     PubMed    
     
     
     
592. CALVO-BARREIRO L, Clerico M, Espejo C
     Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
     Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
     PubMed    
     
     
     
593. HOHLFELD R
     Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
     Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
     PubMed    
     
     
     
594. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
     Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
     Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
     PubMed     Abstract available
     
     
     
595. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
     Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
     Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
     PubMed     Abstract available
     
     
     
596. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
     Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
     Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
     PubMed     Abstract available
     
     
     
597. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
     Staging and stratifying cognitive dysfunction in multiple sclerosis.
     Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
     PubMed     Abstract available
     
     
     
598. BROWNLEE WJ, Solomon AJ
     Misdiagnosis of multiple sclerosis: Time for action.
     Mult Scler. 2021;27:805-806.
     PubMed    
     
     
     
599. CORREA DG, de Souza Lima FC, da Cruz Bezerra D, Coutinho AC Junior, et al
     COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence?
     Mult Scler. 2021;27:973-976.
     PubMed     Abstract available
     
     
     
600. VALENCIA-SANCHEZ C, Flanagan EP
     COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? - Commentary.
     Mult Scler. 2021;27:976-977.
     PubMed    
     
     
     
601. LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
     Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
     Mult Scler. 2021;27:883-894.
     PubMed     Abstract available
     
     
     
602. CAI MT, Zheng Y, Shen CH, Yang F, et al
     Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
     Mult Scler. 2021;27:871-882.
     PubMed     Abstract available
     
     
     
603. CACCIAGUERRA L, Rocca MA, Storelli L, Radaelli M, et al
     Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach.
     Mult Scler. 2021;27:841-854.
     PubMed     Abstract available
     
     
     
604. KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
     Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
     Mult Scler. 2021;27:895-902.
     PubMed     Abstract available
     
     
     April 2021
605. HOLLEN C, Rice J, Park M, Yadav V, et al
     Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
     Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
     PubMed     Abstract available
     
     
     
606. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
     The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
     Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
     PubMed     Abstract available
     
     
     
607. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
     Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
     Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
     PubMed     Abstract available
     
     
     
608. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
     Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
     Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
     PubMed     Abstract available
     
     
     
609. HARRISON AM, Safari R, Mercer T, Picariello F, et al
     Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
     Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
     PubMed     Abstract available
     
     
     
610. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
     Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
     Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
     PubMed     Abstract available
     
     
     
611. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
     Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
     Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
     PubMed     Abstract available
     
     
     
612. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
     Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
     Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
     PubMed     Abstract available
     
     
     
613. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
     Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
     Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
     PubMed     Abstract available
     
     
     
614. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
     Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
     Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
     PubMed     Abstract available
     
     
     
615. FLEMING KM, Coote SB, Herring MP
     Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
     Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
     PubMed     Abstract available
     
     
     
616. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
     Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
     Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
     PubMed     Abstract available
     
     
     
617. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
     Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
     Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
     PubMed     Abstract available
     
     
     
618. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
     Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
     Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
     PubMed     Abstract available
     
     
     
619. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
     Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
     Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
     PubMed     Abstract available
     
     
     
620. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
     COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
     Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
     PubMed     Abstract available
     
     
     
621. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
     A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
     Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
     PubMed     Abstract available
     
     
     
622. VAN DAM M, Hulst HE, Schoonheim MM
     Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
     Mult Scler. 2021;27:491-493.
     PubMed    
     
     
     
623. MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
     Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
     Mult Scler. 2021;27:790-794.
     PubMed     Abstract available
     
     
     
624. BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
     Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
     Mult Scler. 2021;27:729-741.
     PubMed     Abstract available
     
     
     
625. KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
     Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
     Mult Scler. 2021;27:695-705.
     PubMed     Abstract available
     
     
     
626. SECHI E, Messina S, Keegan BM, Buciuc M, et al
     Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
     Mult Scler. 2021;27:667-673.
     PubMed     Abstract available
     
     
     
627. DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
     Cladribine transfer into human milk: A case report.
     Mult Scler. 2021;27:799-801.
     PubMed     Abstract available
     
     
     March 2021
628. MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
     Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
     Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
     PubMed     Abstract available
     
     
     
629. LORSCHEIDER J
     When does a heap become a heap?
     Mult Scler. 2021;27:329-330.
     PubMed    
     
     
     
630. BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
     Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
     Mult Scler. 2021;27:410-419.
     PubMed     Abstract available
     
     
     
631. HYUN JW, Kwon YN, Lee HL, Jeong WK, et al
     Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease.
     Mult Scler. 2021;27:449-452.
     PubMed     Abstract available
     
     
     February 2021
632. BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
     Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
     Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
     PubMed     Abstract available
     
     
     
633. LUCIANI L, Ninove L, Zandotti C, Chalvignac V, et al
     Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease.
     Mult Scler. 2021;27:320-323.
     PubMed     Abstract available
     
     
     
634. SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
     Data harmonization for collaborative research among MS registries: A case study in employment.
     Mult Scler. 2021;27:281-289.
     PubMed     Abstract available
     
     
     
635. SECHI E, Krecke KN, Pittock SJ, Dubey D, et al
     Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
     Mult Scler. 2021;27:303-308.
     PubMed     Abstract available
     
     
     January 2021
636. BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
     An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
     Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
     PubMed     Abstract available
     
     
     
637. ROLLOT F, Casey R, Leray E, Debouverie M, et al
     Cumulative effects of therapies on disability in relapsing multiple sclerosis.
     Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
     PubMed     Abstract available
     
     
     
638. MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
     Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
     Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
     PubMed     Abstract available
     
     
     
639. CARNERO CONTENTTI E, Correale J
     Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - Yes.
     Mult Scler. 2021;27:13-15.
     PubMed    
     
     
     
640. JURYNCZYK M, Messina S, Palace J
     Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - No.
     Mult Scler. 2021;27:15-16.
     PubMed    
     
     
     
641. LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
     Elevated D-dimer as an immediate response to alemtuzumab treatment.
     Mult Scler. 2021;27:151-154.
     PubMed     Abstract available
     
     
     
642. ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
     Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
     Mult Scler. 2021;27:39-51.
     PubMed     Abstract available
     
     
     
643. GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
     Cerebellar volume loss in radiologically isolated syndrome.
     Mult Scler. 2021;27:130-133.
     PubMed     Abstract available
     
     
     December 2020
644. NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
     Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
     Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
     PubMed     Abstract available
     
     
     
645. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
     Serum ceramide levels are altered in multiple sclerosis.
     Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
     PubMed     Abstract available
     
     
     
646. CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
     Depression in multiple sclerosis across the adult lifespan.
     Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
     PubMed     Abstract available
     
     
     
647. TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
     Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
     Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
     PubMed     Abstract available
     
     
     
648. NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
     Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
     Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
     PubMed     Abstract available
     
     
     
649. VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
     Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
     Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
     PubMed     Abstract available
     
     
     November 2020
650. STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
     Youth with multiple sclerosis have low levels of fitness.
     Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
     PubMed     Abstract available
     
     
     
651. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
     Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
     Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
     PubMed     Abstract available
     
     
     
652. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
     Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
     Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
     PubMed     Abstract available
     
     
     
653. PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
     Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
     Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
     PubMed     Abstract available
     
     
     
654. SACCO R, Braga A, Disanto G, Digesu GA, et al
     Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
     Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
     PubMed     Abstract available
     
     
     
655. LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
     Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
     Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
     PubMed     Abstract available
     
     
     October 2020
656. PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
     Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
     Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
     PubMed     Abstract available
     
     
     
657. STRIK M, Chard DT, Dekker I, Meijer KA, et al
     Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
     Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
     PubMed     Abstract available
     
     
     
658. KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
     Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
     Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
     PubMed     Abstract available
     
     
     
659. TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
     Parietal dysfunctional connectivity in depression in multiple sclerosis.
     Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
     PubMed    
     
     
     
660. JAEGER S, Paul F, Finke C
     Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
     Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
     PubMed    
     
     
     
661. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
     Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
     Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
     PubMed     Abstract available
     
     
     
662. VEREB D, Toth E, Bozsik B, Kiraly A, et al
     Altered brain network function during attention-modulated visual processing in multiple sclerosis.
     Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
     PubMed     Abstract available
     
     
     September 2020
663. FERRE L, Mogavero A, Clarelli F, Moiola L, et al
     Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
     Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
     PubMed     Abstract available
     
     
     March 2020
664. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
     Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
     Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
     PubMed     Abstract available
     
     
     
665. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
     Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
     Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
     PubMed     Abstract available
     
     
     
666. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
     Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
     Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
     PubMed     Abstract available
     
     
     
667. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
     Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
     Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
     PubMed     Abstract available
     
     
     
668. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
     Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
     Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
     PubMed     Abstract available
     
     
     
669. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
     Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
     Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
     PubMed     Abstract available
     
     
     
670. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
     Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
     Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
     PubMed     Abstract available
     
     
     
671. BERTOLI M, Tecchio F
     Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
     Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
     PubMed     Abstract available
     
     
     
672. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
     Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
     Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
     PubMed     Abstract available
     
     
     
673. NG HS, Kingwell E, Zhu F, Zhang T, et al
     Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
     Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
     PubMed     Abstract available
     
     
     
674. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
     Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
     Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
     PubMed     Abstract available
     
     
     February 2020
675. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
     Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
     Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
     PubMed     Abstract available
     
     
     
676. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
     Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
     Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
     PubMed     Abstract available
     
     
     
677. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
     ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
     Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
     PubMed     Abstract available
     
     
     
678. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
     Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
     Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
     PubMed     Abstract available
     
     
     
679. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
     Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
     Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
     PubMed     Abstract available
     
     
     
680. MCKEON A, Zekeridou A
     Autoimmune encephalitis management: MS centers and beyond.
     Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
     PubMed     Abstract available
     
     
     
681. SON M, McEwan L, Ubaidat M, Bovell K, et al
     Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
     Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
     PubMed     Abstract available
     
     
     
682. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
     Leptin levels are associated with multiple sclerosis risk.
     Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
     PubMed     Abstract available
     
     
     
683. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
     Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
     Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
     PubMed     Abstract available
     
     
     January 2020
684. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
     A critical analysis of helminth immunotherapy in multiple sclerosis.
     Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
     PubMed     Abstract available
     
     
     
685. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
     Recovery of cognitive function after relapse in multiple sclerosis.
     Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
     PubMed     Abstract available
     
     
     
686. CARNERO CONTENTTI E, Giachello S, Correale J
     Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
     Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
     PubMed     Abstract available
     
     
     
687. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
     Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
     Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
     PubMed     Abstract available
     
     
     
688. CORTESE R, Tur C, Prados F, Schneider T, et al
     Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
     Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
     PubMed     Abstract available
     
     
     
689. SALTER A, Fox RJ, Tyry T, Cutter G, et al
     New applications for independent activities of daily living in measuring disability in multiple sclerosis.
     Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
     PubMed     Abstract available
     
     
     December 2019
690. CROUSE DL, Foroughi I, Gupta N
     Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
     Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
     PubMed     Abstract available
     
     
     
691. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
     High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
     Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
     PubMed     Abstract available
     
     
     
692. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
     Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
     Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
     PubMed     Abstract available
     
     
     
693. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
     Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
     Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
     PubMed     Abstract available
     
     
     
694. HOLTON KF, Kirkland AE
     Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
     Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
     PubMed     Abstract available
     
     
     
695. RAHNAMA'I MS
     Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
     Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
     PubMed     Abstract available
     
     
     
696. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
     Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
     Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
     PubMed     Abstract available
     
     
     November 2019
697. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
     Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
     Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
     PubMed     Abstract available
     
     
     
698. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
     Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
     Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
     PubMed     Abstract available
     
     
     
699. LI CMF, Hung PS, Chu PP, Tohyama S, et al
     Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
     Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
     PubMed     Abstract available
     
     
     
700. COMI G, Alroughani R, Boster AL, Bass AD, et al
     Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
     Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
     PubMed     Abstract available
     
     
     
701. KIM JE, Park SH, Han K, Kim HJ, et al
     Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
     Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
     PubMed     Abstract available
     
     
     
702. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
     Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
     Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
     PubMed     Abstract available
     
     
     
703. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
     On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
     Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
     PubMed     Abstract available
     
     
     
704. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
     Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
     Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
     PubMed     Abstract available
     
     
     
705. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
     Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
     Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
     PubMed     Abstract available
     
     
     
706. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
     Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
     Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
     PubMed     Abstract available
     
     
     
707. COLLORONE S, Cawley N, Grussu F, Prados F, et al
     Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
     Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
     PubMed     Abstract available
     
     
     
708. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
     Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
     Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
     PubMed     Abstract available
     
     
     
709. KUHLE J, Plavina T, Barro C, Disanto G, et al
     Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
     Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
     PubMed     Abstract available
     
     
     
710. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
     Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
     Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
     PubMed     Abstract available
     
     
     October 2019
711. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
     Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
     Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
     PubMed     Abstract available
     
     
     
712. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
     eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
     Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
     PubMed     Abstract available
     
     
     
713. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
     Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
     Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
     PubMed     Abstract available
     
     
     
714. BSTEH G, Berek K, Hegen H, Teuchner B, et al
     Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
     Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
     PubMed     Abstract available
     
     
     
715. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
     Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
     Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
     PubMed     Abstract available
     
     
     
716. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
     Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
     Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
     PubMed     Abstract available
     
     
     
717. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
     Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
     Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
     PubMed     Abstract available
     
     
     
718. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
     Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
     Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
     PubMed     Abstract available
     
     
     
719. ZECCA C, Bovis F, Novi G, Capobianco M, et al
     Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
     Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
     PubMed     Abstract available
     
     
     June 2019
720. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
     T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
     Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
     PubMed     Abstract available